

The *Alu*-Rich Genomic Architecture of *SPAST* Predisposes to Diverse and Functionally Distinct Disease-Associated CNV Alleles

Philip M. Boone,¹ Bo Yuan,¹ Ian M. Campbell,¹ Jennifer C. Scull,² Marjorie A. Withers,¹ Brett C. Baggett,¹ Christine R. Beck,¹ Christine J. Shaw,¹ Pawel Stankiewicz,^{1,2} Paolo Moretti,^{1,3,4} Wendy E. Goodwin,⁵ Nichole Hein,⁶ John K. Fink,^{6,7,8} Moon-Woo Seong,⁹ Soo Hyun Seo,⁹ Sung Sup Park,⁹ Izabela D. Karbassi,¹⁰ Sat Dev Batish,¹⁰ Andrés Ordóñez-Ugalde,¹¹ Beatriz Quintáns,¹¹ María-Jesús Sobrido,¹¹ Susanne Stemmler,¹² and James R. Lupski^{1,2,13,14,*}

Intragenic copy-number variants (CNVs) contribute to the allelic spectrum of both Mendelian and complex disorders. Although pathogenic deletions and duplications in *SPAST* (mutations in which cause autosomal-dominant spastic paraplegia 4 [SPG4]) have been described, their origins and molecular consequences remain obscure. We mapped breakpoint junctions of 54 *SPAST* CNVs at nucleotide resolution. Diverse combinations of exons are deleted or duplicated, highlighting the importance of particular exons for spastin function. Of the 54 CNVs, 38 (70%) appear to be mediated by an *Alu*-based mechanism, suggesting that the *Alu*-rich genomic architecture of *SPAST* renders this locus susceptible to various genome rearrangements. Analysis of breakpoint *Alus* further informs a model of *Alu*-mediated CNV formation characterized by small CNV size and potential involvement of mechanisms other than homologous recombination. Twelve deletions (22%) overlap part of *SPAST* and a portion of a nearby, directly oriented gene, predicting novel chimeric genes in these subjects' genomes. cDNA from a subject with a *SPAST* final exon deletion contained multiple *SPAST:SLC30A6* fusion transcripts, indicating that *SPAST* CNVs can have transcriptional effects beyond the gene itself. *SLC30A6* has been implicated in Alzheimer disease, so these fusion gene data could explain a report of spastic paraplegia and dementia cosegregating in a family with deletion of the final exon of *SPAST*. Our findings provide evidence that the *Alu* genomic architecture of *SPAST* predisposes to diverse CNV alleles with distinct transcriptional—and possibly phenotypic—consequences. Moreover, we provide further mechanistic insights into *Alu*-mediated copy-number change that are extendable to other loci.

Introduction

DNA copy-number variants (CNVs) deleting or duplicating parts of genes contribute to exon shuffling and gene evolution, thus playing an important role in both Mendelian and common/complex traits.^{1–4} CNVs in *SPAST* (2p22.3 [MIM 604277]) cause 8%–41% of autosomal-dominant spastic paraplegia 4 (SPG4 [MIM 182601]),^{5–7} the predominant form of hereditary spastic paraplegia (HSP).^{8,9} Heterozygous CNVs deleting ($n > 70$ cases) and duplicating ($n = 2$ cases) various *SPAST* exons or the entire *SPAST* gene have been described.^{10,11} However, it is not known how these CNVs form, whether and/or why *SPAST* is particularly susceptible to these rearrangements, and what the consequences of *SPAST* CNVs, either molecular or phenotypic, are in comparison to other types of mutations in the same gene.

Multiple molecular mechanisms have been described or proposed to generate small CNVs^{12,13} commensurate with the genic/exonic scale of many or most rearrangements

described in *SPAST*.¹⁴ Insights into the mechanism(s) of *SPAST* CNV formation, however, are largely absent because of methodological limitations: CNVs in *SPAST* are usually studied with multiplex ligation-dependent probe amplification (MLPA),⁶ a method that reveals the copy number of each of the 17 *SPAST* exons but leaves the exact location, sequence, and characteristics of CNV boundaries (i.e., breakpoint junctions) unknown.

We previously ascertained the nucleotide sequence of breakpoint junctions for three *SPAST* CNVs deleting the final exon of the gene.¹⁴ Although the size and genomic position of each deletion differed, all deletion breakpoints localized to pairs of directly oriented *Alu* elements, a repetitive DNA element of ~300 base pairs (bp) present in $>10^6$ copies in the human genome.¹⁵ This *Alu*-*Alu*-mediated rearrangement phenomenon has been reported in studies of small, germline CNVs at other disease loci,^{16–20} somatic rearrangements found in malignancies,^{20,21} and rearrangements arising during human evolution.^{22–24} Such variation has generally been attributed to *Alu*-*Alu*

¹Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; ²Medical Genetics Laboratories, Baylor College of Medicine, Houston, TX 77030, USA; ³Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA; ⁴Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA; ⁵Children's Medical Center of Dallas, Dallas, TX 75207, USA; ⁶Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA; ⁷Geriatrics Research Education and Clinical Center, Ann Arbor, MI 48105, USA; ⁸Veterans Affairs Medical Center, Ann Arbor, MI 48015, USA; ⁹Department of Laboratory Medicine, Seoul National University Hospital, Seoul 110-799, Korea; ¹⁰Quest Diagnostics, Athena Diagnostics, Worcester, MA 01605, USA; ¹¹Fundación Pública Galega de Medicina Xenómica-SERGAS, IDIS, CIBERER, Santiago de Compostela 15706, Spain; ¹²Department of Human Genetics, Ruhr University, Bochum 44801, Germany; ¹³Texas Children's Hospital, Houston, TX 77030, USA; ¹⁴Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA

*Correspondence: jlupski@bcm.edu

<http://dx.doi.org/10.1016/j.ajhg.2014.06.014>. ©2014 by The American Society of Human Genetics. All rights reserved.

recombination, a proposed molecular mechanism in which homologous recombination (HR) utilizes nonallelic *Alu* pairs as substrates to generate CNVs.^{20,25} Intriguingly, the CNVs in our small cohort exhibited features potentially inconsistent with formation by ectopic homologous recombination: one CNV was potentially complex, and breakpoint *Alu* pairs shared <90% identity. The remaining four *SPAST* CNVs with known breakpoints do not localize to *Alus*.^{11,26–28} Therefore, we sought to further investigate the mechanism(s) generating *SPAST* CNVs, including the way in which the *Alu*-rich architecture of *SPAST*¹⁴ might render this gene or particular exons within it susceptible to CNV mutations.

SPG4, the clinical phenotype associated with *SPAST* mutation, is predominately characterized by progressive lower-limb weakness and spasticity caused by degeneration of upper motor neurons in the corticospinal tract.²⁹ Occasional reports of additional phenotypes suggestive of CNS pathology exist,^{30–32} and subtle cognitive impairment has been suggested to be a moderately penetrant feature of the disease (reviewed by Dürr et al. in GeneReviews). Furthermore, severity and age of onset can vary. No consistent genotype-phenotype correlation exists for alleles in *SPAST*.³³ Most disease-causing variants have been thought to represent loss-of-function alleles. However, we previously hypothesized that a subset of *SPAST* CNVs—those overlapping the 3' end of the gene—might also affect expression of *SLC30A6* (MIM 611148), the nearest gene to *SPAST*, located 8 kb downstream.¹⁴ *SLC30A6* encodes a zinc transporter, ZnT6. Although *SLC30A6* variants have not been found in association with any disease, zinc transporter (including ZnT6) dynamics are altered in the brains of some individuals with Alzheimer disease.^{34,35} Thus, we investigated the possibility of *SPAST* CNVs dysregulating *SLC30A6* expression, particularly given reports of individuals with comorbid spastic paraplegia and dementia.^{31,36}

We studied *SPAST* CNVs in an additional 51 subjects and now report diverse CNVs for which *Alu*-mediated formation predominates. These CNVs rearrange a variety of exons including 24 (47%) affecting the final (3') exon of the gene and potentially forming fusion transcripts with or altering expression of *SLC30A6* and other adjacent genes. In cultured lymphoblastoid cells from one subject with a *SPAST* exon 17 deletion, we identify multiple *SPAST*:*SLC30A6* fusion transcripts. Finally, we propose alternative models to homologous recombination for *Alu*-mediated CNV formation based upon the observed breakpoint features of CNVs in *SPAST*; these are extendable to other loci, potentially enabling genome-wide predictions of *Alu*-mediated genome instability.

Subjects and Methods

Subjects

Subjects consisted primarily of individuals with a clinical diagnosis of spastic paraplegia and a previous finding of a *SPAST*

CNV identified during clinical laboratory screening or a family-based research study (Table S1 available online). This study was approved by the Institutional Review Board for Human Subjects Research of Baylor College of Medicine (H-28128, H-25466, H-9170, H-29697). Remaining DNA samples were deidentified for our analyses. Subjects are further described in Tables 1 and S1. Owing to the anonymized nature of sample acquisitions, phenotypic details beyond a clinical diagnosis of spastic paraplegia are unknown in most cases. Samples from Athena Diagnostics were intentionally enriched for exon 17 CNVs. All other sources contributed all available CNVs in their collections.

Mapping CNV Breakpoints

DNA was extracted from whole blood using the Gentra Puregene Blood Kit (QIAGEN) or obtained from previously archived samples. A total of 50 CNVs in *SPAST* were confirmed and mapped using a custom comparative genomic hybridization (CGH) array targeted to *SPAST* and flanking regions (approximately one megabase 5' and 3'). This Agilent 8 × 15 k probe oligonucleotide array (format = G4427A; design ID = 037541) was custom designed using Agilent eArray and contains approximately one probe per 200 base pairs (bp) throughout the targeted region. Array CGH procedures have been described.³⁷ Hybridization controls were gender matched unless an individual's gender was unknown, in which cases female DNA (HapMap individual NA15510) was used. Array image files were processed using Agilent Feature Extraction software (v.10) and CNVs called with Agilent Genomic Workbench software (v.7). One CNV (Ruhr 29) was mapped using a genome-wide Agilent 1M probe oligonucleotide CGH array (format = G4824A; design ID = 02159) because the CNV extended beyond the boundaries of our targeted array.

CNVs were further confirmed and mapped by long-range PCR with primers (Table S2) spanning their predicted breakpoints. PCR reagents and concentrations have been described previously.³⁸ The thermal cycler was programmed as follows: 94°C × 1 min; 30 cycles of 94°C × 30 s followed by 68°C × 7 min; 72°C × 10 min. Breakpoint PCR products were treated with ExoStar (GE Healthcare) according to the manufacturer's instructions or extracted from an agarose gel using the Zymoclean gel DNA recovery kit (Zymo Research), also according to the manufacturer's instructions, then sequenced by Sanger di-deoxynucleotide sequencing (Lone Star Labs; SeqWright; Baylor College of Medicine Sequencing Core, Houston, TX, USA).

All genomic coordinates are based on the February 2009 genome build (GRCh37/hg19) unless otherwise specified. *SPAST* exon numbering is based on UCSC transcript variant uc002roc.3 (17 exons). *SLC30A6* exon numbering is based on UCSC transcript variant uc002rof.2 (15 exons).

STR Analysis

Alleles at 15 short tandem repeats (STRs) and subject gender were assessed using the Applied Biosystems AmpFISTR Identifier Direct PCR Amplification Kit (Life Technologies) according to the manufacturer's instructions.

Haplotype Analysis

For each deletion found in multiple individuals, primer pairs (Table S2) were designed to amplify 5–10 kb flanking each side of the deletion. The deleted allele was selectively amplified or was isolated based on size by gel extraction as described above. Common SNPs (allele frequency ≥ 1% in dbSNP 138) within these

amplicons were genotyped by Sanger sequencing using a custom set of sequencing primers (Table S2). To assess the frequency of the observed haplotypes in the population, we obtained 1,984 phased haplotypes from the 1000 Genomes Project.³⁹

Cell Lines

Lymphoblasts were isolated from whole blood collected in acid citrate dextrose (ACD) tubes and transformed with Epstein-Barr virus to make lymphoblastoid cell lines (LCLs) by the Baylor College of Medicine Intellectual and Developmental Disabilities Research Center Tissue Culture Core. LCLs were cultured in GIBCO RPMI 1640 media with 20% FBS, then 10% FBS, and 1% antimycotic/antibiotic (all from Life Technologies) in 5% CO₂.

RNA Extraction and cDNA Synthesis

Total RNA was extracted from confluent, transformed lymphoblastoid cells using TRIzol (Invitrogen). RNA was cleaned using the RNeasy kit (QIAGEN) and quantitated with a NanoDrop ND-1000 spectrophotometer (NanoDrop). Complementary DNA (cDNA) was synthesized using qScript cDNA SuperMix (Quanta Biosciences) according to the manufacturer's instructions (input = 1 µg RNA). cDNA quality was assessed via gel electrophoresis (not shown). A mock cDNA synthesis reaction performed without the reverse transcriptase mixture served as a negative ("No RT") control during cDNA PCR.

PCR and Sequencing of cDNA

cDNA (2 µl) was used as PCR substrate in a 25 µl reaction mix containing 0.5 µM of each primer (Table S2) and 1× Promega PCR Master Mix (Promega). Thermocycler conditions were as follows: 95°C × 2 min; 40 cycles of 95°C × 30 s, 57°C × 30 s, 72°C × 3 min; 72°C × 5 min. PCR products were sequenced by Sanger di-deoxynucleotide sequencing (Lone Star labs; Baylor College of Medicine Sequencing Core, Houston, TX, USA) using the above cDNA PCR primers.

Quantitative RT-PCR

Quantitative RT-PCR (qPCR) assessing the expression level of *SLC30A6* was performed using the TaqMan assay (Life Technologies). The Hs01071782_m1 probe set was used for *SLC30A6* (spans the boundary of exon 9 and exon 10). The Hs02758991_g1 probe set was used for *GAPDH* (control gene [MIM 138400]; probe set spans the boundary of exon 6 and exon 7). The PCR amplification step was performed with 1 µl cDNA utilizing TaqMan Fast Advanced Master Mix (Life Technologies) and the 7900HT Fast Real-Time PCR System (Applied Biosystems). Three technical replicates were performed for each sample (subject or control).

The comparative Ct method was used to generate the relative quantification (Δ Ct) of the expression level of *SLC30A6* over *GAPDH* in an individual. The distribution of the Δ Ct for *SLC30A6* was established by the control samples. The *SLC30A6* Δ Ct for the subject was compared to this distribution using the empirical cumulative distribution function.

Results

SPAST CNVs Exhibit Diverse Sizes, Genomic Positions, and Exons Rearranged

We analyzed 51 heterozygous CNVs in *SPAST* (48 deletions and 3 duplications), predominately identified in individ-

uals with a diagnosis of spastic paraplegia (Table 1). CNVs were most commonly discovered by multiplex ligation-dependent probe amplification (MLPA; data not shown). MLPA indicates only the exon(s) deleted or duplicated by a CNV, not its boundaries (breakpoints), so we fine-mapped each rearrangement using array comparative genomic hybridization (aCGH). Array CGH confirmed each CNV (Figures 1 and S1) and determined the approximate size, extent, and genomic content of each rearranged interval, enabling junction-spanning (breakpoint) PCR and sequencing reactions to be performed. PCR amplified 50 of 51 (98%) CNV breakpoints (Figure S2), and sequencing delineated the breakpoint sequence and exact coordinates of 49 (98%) of these rearrangements (Figure S3; 46 deletions and 3 duplications).

A diversity of CNV alleles were identified (Tables 1 and S1, Figure 2A). To date, 40 different combinations of *SPAST* exons have been reported to be deleted in individuals with spastic paraplegia, and 2 duplicated;^{5,9,14,40,41} we now contribute 12 novel rearrangements of *SPAST* exons (Table 1), including 2 novel duplications.

Of the CNVs we report, 36 (71%) occur in a single subject, and five groups of individuals had identical (shared regions of breakpoint microhomology) *SPAST* CNVs: Ruhr 9 and Ruhr 10 (del exon 1); Ruhr 3 and Ruhr 5 (del exons 2–9); Ruhr 13 and Ruhr 18 (del exons 8–17 and exon 1 of *SLC30A6*); A4, A8, A9, and *SPAST_1* (partial del exon 17); and A1 and BAB 3327 (del exon 17; also identical to A39 from Boone et al.¹⁴). Identical CNVs in multiple subjects suggests either recurrent CNV formation or that individuals within a group are related or are the same individual. To investigate these possibilities, we analyzed 15 short tandem repeat alleles (STRs) and gender in these individuals (Table S3). No subjects sharing an identical CNV were monozygotic twins or the same individual, and in only one case (A1 and BAB 3327) were two such individuals consistent with a parent-child pair. To identify whether identical CNVs are observed on the same haplotype (i.e., potentially identical by descent) or on different haplotypes (i.e., identical by state, suggesting recurrent events), common SNPs flanking the CNVs were genotyped to establish a local haplotype. No flanking SNPs differ among individuals sharing the same CNV, thus failing to provide specific evidence for recurrence (Figure S6). For CNVs shared between Ruhr 13 and Ruhr 18, the haplotype surrounding the CNV is uncommon (5.1%), making recurrent events particularly unlikely. In other groups, the CNVs occurred on the most common haplotype.

We combined data from the 49 CNV breakpoint junctions delineated above with data from five *SPAST* CNVs we reported previously^{14,26,27} and three additional published *SPAST* CNVs,^{11,28,40} totaling 57 rearrangements and representing every *SPAST* CNV >30 bp for which exact breakpoint coordinates have been identified (Tables 1 and S1; Figure 2A). These CNVs range from 1,340 bp to 1,283,930 bp in size, with a mean of 73.1 kb, a median of 16.5 kb, and a distribution skewed toward smaller

Table 1. Subjects and SPAST CNVs

Subject	Del versus Dup	SPAST Exon(s) Affected (of 17)	Other Genes Deleted or Duplicated	CNV Size (kb)	Spastic Paraplegia	Origin	Novel Rearrangement ^a	Notes
A1	del	17	–	5.5	y	USA	–	
A2	del	17	–	14.4	y	USA	–	complex
A3	del	17	<i>SLC30A6</i> ex 1–5 (of 15)	24.6	y	USA	–	
A4	del	17 (partial)	–	2.7	y	USA	y	
A5	del	17	<i>SLC30A6</i> ex 1–2 (of 15)	18.4	y	USA	–	
A6	del	17	<i>SLC30A6</i> ex 1–2 (of 15)	25.7	y	USA	–	
A8	del	17 (partial)	–	2.7	y	USA	y	
A9	del	17 (partial)	–	2.7	y	USA	y	
A10	dup	13–15	–	6.2	y	USA	y	tandem, directly oriented duplication
BAB 3166	del	13	–	1.3	n (at age 16)	USA	NA	reported in Boone et al. ²⁶
BAB 5112	del	5–17	<i>SLC30A6</i> , <i>NLRC4</i> , <i>YIPF4</i> , <i>BIRC6</i> , <i>MIR558</i> , <i>MIR4765</i> , and <i>TTC27</i> ex 1–5 (of 20)	559.3	y	USA	y	
BAB 3200	del	1–7	<i>DPY30</i> ex 1–3 (of 5)	87.2	y	USA	NA	complex; reported in de Ligt et al. ²⁷
BAB 3327	del	17	–	5.5	y	USA	–	
SPAST_1	del	17 (partial)	–	2.7	? ^b	USA	y	
SPAST_3	dup	2–17	<i>SLC30A6</i> , <i>NLRC4</i> , <i>YIPF4</i> , and <i>BIRC6</i> ex 1–46 (of 74)	432.2	? ^b	USA	y	tandem, directly oriented duplication
Spain 1	del	5–16	–	43.4	y	Spain	y	
Spain 2	del	13–17	<i>SLC30A6</i> , <i>NLRC4</i> , <i>YIPF4</i> , <i>MIR558</i> , and <i>BIRC6</i> ex 1–66 (of 74)	455.0	y	Spain	y	
Spain 3	del	3–17	<i>SLC30A6</i> ex 1–5 (of 15)	95.7	y	Spain	–	
Spain 4	del	8–17	<i>SLC30A6</i> ex 1–5 (of 15)	60.7	y	Spain	–	
Spain 5	del	1	–	12.6	y	Spain	–	
Spain 6	del	2–17	<i>SLC30A6</i> and <i>NLRC4</i> ex 5–9 (of 9)	170.1	y	Spain	–	
Spain 7	del	10–16	–	16.0	y	Spain	–	
Spain 8	del	2–7	–	48.9	y	Spain	y	
Spain 9	del	6–7	–	5.0	y	Spain	–	
JKF B	del	16	–	2.0	y	USA	–	
JKF C	dup	9	–	6.7	y	USA	y	tandem, directly oriented duplication
Ruhr 3	del	2–9	–	65.4	y	Germany	–	
Ruhr 4	del	1	–	20.5	y	Germany	–	
Ruhr 5	del	2–9	–	65.4	y	Germany	–	
Ruhr 6	del	5–6	–	8.3	y	Germany	–	
Ruhr 7	del	17 (partial)	–	5.1	y	Germany	y	
Ruhr 9	del	1	–	4.0	y	Germany	–	
Ruhr 10	del	1	–	4.0	y	Germany	–	
Ruhr 11	del	2–7	–	33.5	y	Germany	y	

(Continued on next page)

Table 1. Continued

Subject	Del versus Dup	SPAST Exon(s) Affected (of 17)	Other Genes Deleted or Duplicated	CNV Size (kb)	Spastic Paraplegia	Origin	Novel Rearrangement ^a	Notes
Ruhr 12	del	1	–	16.3	y	Germany	–	
Ruhr 13	del	8–17	<i>SLC30A6</i> ex 1 (of 15)	44.8	y	Germany	–	
Ruhr 14	del	16–17	<i>SLC30A6</i> ex 1–4 (of 15)	31.7	y	Germany	–	
Ruhr 15	del	2–12	–	72.9	y	Germany	y	
Ruhr 16	del	5	–	1.9	y	Germany	–	
Ruhr 17	del	9–17 (partial)	–	27.5	y	Germany	y	
Ruhr 18	del	8–17	<i>SLC30A6</i> ex 1 (of 15)	44.8	y	Germany	–	
Ruhr 21	del	10–17 (partial)	–	20.9	y	Germany	y	
Ruhr 23	del	17	–	17.6	y	Germany	–	
Ruhr 26	del	13–16	–	7.3 ^c	y	Germany	–	
Ruhr 27	del	17	<i>SLC30A6</i> ex 1–2 (of 15)	24.1	y	Germany	–	complex
Ruhr 28	del	1 (partial)	–	16.5	y	Germany	–	
Ruhr 29	del	8–17	<i>SLC30A6, NLRC4, YIPF4, BIRC6, MIR558, MIR4765, TTC27, LINC00486, LOC100271832, LTBP1, 5S_rRNA</i>	1,283.9	y	Germany	–	
Ruhr 31	del	8–9	–	9.3	y	Germany	–	
Ruhr 32	del	2–13	–	59.4 ^c	y	Germany	y	
Park 1	del	5–7	–	11.7	y	Korea	–	
Park 2	del	5 (partial)–7	–	8.1	y	Korea	y	
Park 3	del	8–9	–	8.9	y	Korea	–	
Park 4	del	4–17	<i>SLC30A6</i> ex 1–9 (of 15)	100.5	y	Korea	–	
A37	del	17	–	10.8	y	USA	NA	reported in Boone et al. ¹⁴
A38	del	17	–	16.8	y	USA	NA	complex; reported in Boone et al. ¹⁴
A39	del	17	–	5.5	y	USA	NA	reported in Boone et al. ¹⁴
Iwanaga	del	1 (partial)	–	2.3	y	Japan	NA	reported in Iwanaga et al. ²⁸
Mitne-Neto	dup	10–12	–	4.0	y	Brazil	NA	reported in Mitne-Neto et al. ¹¹ ; tandem, directly oriented duplication
Miura	del	1–4	<i>DPY30</i> ex 1–3 (of 5)	69.8	y	Japan	NA	reported in Miura et al. ⁴⁰

Abbreviations are as follows: ex, exon; y, yes; n, no; NA, not applicable; –, no or none.

^aBased on *SPAST* exon or combination of exons rearranged and ploidy (del versus dup). Rearrangement of part of an exon is considered to be distinct from rearrangement of the whole exon. Previously published CNVs derived from Loureiro et al.,⁵ Álvarez et al.,⁹ Boone et al.,^{14,26} Sulek et al.,⁴¹ and Myers et al.⁴²

^bPhenotype unknown.

^cCNV breakpoint could not be sequenced. CNV length is an average of the minimum and maximum CNV interval identified by aCGH.

rearrangements (Figure 3). Thus, the majority of *SPAST* CNVs are of modest size when compared with the gene itself (94 kb).

All known *SPAST* duplications (Table 1, Figure 2) are tandem and directly oriented. We previously noted that *SPAST* duplications are significantly underrepresented when

compared with deletions among subjects with SPG4,¹⁴ a trend that continues in the data presented here (Table 1). The pathogenic duplications in subjects A10 (exons 13–15) and Mitne-Neto (exons 10–12) are both expected to shift the reading frame; interestingly, the pathogenic duplication in JKF C (exon 9) is predicted to be in-frame.




Figure 1. Targeted aCGH Confirms and Maps CNVs in *SPAST*

Array CGH log₂ plots are aligned with models of *SPAST* and nearby genes. Very small CNVs are indicated by arrows. Coordinates refer to chromosome 2. No *SPAST* CNV was identified in either blood- or cell-culture-derived DNA from the control individual, BAB 3099.




Figure 2. CNVs in *SPAST* Rearrange Diverse Exons and Have Breakpoints Predominately Localizing to Pairs of *Alu* in Direct Orientation

(A) CNVs are plotted by exact coordinates obtained by sequencing (black bars) and include both duplications (denoted “Dup”) and deletions (all others). Repetitive elements at CNV breakpoints are indicated by colored shapes and aligned with the RepeatMasker track (bottom, via UCSC Genome Browser) by colored lines. The genomic orientation of *Alus* is denoted by a right-facing (+) or left-facing (–) pentagon. Of 59 breakpoints, 39 (66%) localize to directly oriented *Alu* pairs. Note that BAB 3166 was identified in a young individual with no current spastic paraplegia²⁶ and that the phenotypes of *SPAST*_1 and *SPAST*_3 are unknown; thus, these three CNVs might or might not be pathogenic. *Complex CNV (these CNVs are plotted as simple CNVs with only the first and final breakpoint repeat indicated). The breakpoints of Ruhr 26 and Ruhr 32 were not found, so these CNVs are not included.

(B) A moving average of *Alu* density (calculated in overlapping blocks of ten *Alu* elements) is aligned with (A), demonstrating that *SPAST* is overall an *Alu*-rich gene with “neighborhoods” of even higher *Alu* density. *Alu* data were downloaded from RepeatMasker.

(C) Zoomed-out plot of *Alu* density over a ~1.1 Mb section of chromosome 2.

CNV Breakpoints Predominately Localize to Pairs of *Alu* Elements in Direct Orientation

CNV boundaries, or breakpoints, occasionally preferentially localize to repetitive genomic elements, which can

play a role in mediating CNV formation.^{13,18} Repetitive elements present at the breakpoints of *SPAST* CNVs are shown in Figure 2 and listed in Table 2. Of 57 sequenced *SPAST* CNV breakpoints, 39 (68%) localize to directly




Figure 3. CNV Size: Skew toward Small Rearrangements and Association with Breakpoint Repeat Architecture
 SPAST CNVs, plotted in ascending size order. Most SPAST CNVs are small (median size = 16.5 kb). CNVs flanked by *Alu* pairs (gray) are significantly smaller than remaining CNVs (green) (Kruskal-Wallis rank sum test, $p = 0.00856$; identical CNVs in multiple individuals [e.g., Ruhr 3 and 5] are collapsed to single entries, and CNVs published by other authors [which may be biased toward small, non-*Alu*-*Alu*-mediated events] are removed). *Complex CNV. BAB 5112 is LINE-LINE mediated. CNVs <25 kb are magnified in the inset to show detail. The size of complex CNVs is rounded to the nearest 0.1 kb.

oriented pairs of *Alu* repeats. Such CNVs demonstrate breakpoint “signatures” consistent with *Alu*-mediated CNV formation (i.e., the rearranged genome contains a complete hybrid *Alu*, each “half” of which is derived from one of the two breakpoint *Alus* that flanked the deleted or duplicated region prior to its loss or gain, respectively;²² Figure S3).

Breakpoint *Alu* pairs exhibit variable sequence identity (range = 75.8%–90.7%), possess differing numbers of bases of microhomology at the hybrid junction (range = 5–38 bp), and comprise distinct *Alu* families (Table 2). Of the 39 breakpoint *Alu* pairings, 33 (85%) consist of *Alus* from different families. Several *Alus* are present at the breakpoints of multiple CNVs. These data are consistent with analyses of multiple *Alu*-mediated CNVs at additional disease loci (Table 4). The repeat present at a breakpoint of the greatest number of different CNVs is an *AluY* (Spain 7, A38, Ruhr 23, Ruhr 27, A6), as observed previously.¹⁶ Breakpoint crossover/microhomology locations occupy various positions within the *Alu* substrate pairs (Figure S4).

The eight largest CNVs are not *Alu* mediated (Figure 3). To determine statistically whether CNV size correlates with the presence or absence of *Alus* at CNV breakpoints, we collapsed CNVs found in multiple individuals (e.g., Ruhr 3 and 5) into single entries and removed the three SPAST CNVs described by other authors, which may be biased toward small, non-*Alu*-mediated events because such CNVs are more readily mapped and sequenced.

Among this data set, CNVs flanked by *Alu* pairs are significantly smaller than non-*Alu*-mediated CNVs (Figure 3; Kruskal-Wallis rank sum test, $p = 0.00856$).

Three CNVs with proximal and distal breakpoints in *Alus* are potentially complex (A38, A2, and Ruhr 27). A38 has been described¹⁴ and is consistent with formation by two or three template switches during DNA replication or by NAHR and a novel, familial *Alu* polymorphism. The origin of A2 is consistent with two template switches or a small (11 bp) insertion. The origin of Ruhr 27 is consistent with two template switches, two distinct NAHR events, or an NAHR event and a novel, familial *Alu* polymorphism. It is unknown whether any of these CNVs is de novo, and parental DNA is unavailable.

In addition to the 39 CNVs in our cohort with pairs of *Alus* at breakpoints, other signatures are present in 32% of junctional sequences. These include 13 instances of microhomology not localizing to repeat pairs, two apparently blunt end “clean breaks,” one LINE-LINE recombination (BAB 5112), one 1 bp insertion, and one potentially complex CNV (BAB 3200) (Figure S3).

Some Breakpoint *Alus* Contain a 13-nt Consensus Motif Enriched at Meiotic Recombination Hotspots

A 13-nucleotide motif (consensus = CCNCCNTNCCNC) has been delineated and found in proximity to and in association with >40% of meiotic recombination crossover hotspots, at NAHR crossover hotspots in low-copy repeats flanking some genomic disorder regions, and is bound

Table 2. Repeats Present at CNV Breakpoints^a

Subject	Left Breakpoint Repeat	Right Breakpoint Repeat	Microhomology (bp)	% Identity of Repeats ^b
A1	<i>AluSx^c</i>	<i>AluY</i>	26	81.7
A2 ^c	<i>AluSx</i>	<i>AluSx1</i>	complex	complex
A3	<i>AluSx1^c</i>	<i>AluY</i>	7	86.9
A4	<i>AluSx1^c</i>	<i>AluSp</i>	15	84.8
A5	<i>AluSx1^c</i>	<i>AluSp</i>	9	88.6
A6	<i>AluY</i>	<i>AluSx3^c</i>	21	84.6
A8	<i>AluSx1^c</i>	<i>AluSp</i>	15	84.8
A9	<i>AluSx1^c</i>	<i>AluSp</i>	15	84.8
A10	<i>AluSz6</i>	<i>AluSg</i>	31	80.1
BAB 3166	–	–	6	–
BAB 5112	L1PA5	L1PA7	21	90.6
BAB 3200	<i>AluSc</i>	–	complex	–
BAB 3327	<i>AluSx^c</i>	<i>AluY</i>	26	81.7
SPAST_1	<i>AluSx1^c</i>	<i>AluSp</i>	15	84.8
SPAST_3	–	–	4	–
Spain 1	L1PA5	<i>AluJb</i>	4	–
Spain 2	–	<i>AluSp</i>	2	–
Spain 3	<i>AluSz6</i>	–	2	–
Spain 4	<i>AluSq</i>	L1M4	8	–
Spain 5	<i>AluSz</i>	<i>AluSz</i>	26	80.6
Spain 6	<i>AluSg4</i>	–	1	–
Spain 7	<i>AluSc</i>	<i>AluY</i>	15	84.6
Spain 8	<i>AluSg4</i>	<i>AluY^c</i>	9	83.7
Spain 9	–	–	6	–
JKF B	<i>AluSg</i>	<i>AluY</i>	14	82.1
JKF C	<i>AluSz</i>	<i>AluSx^c</i>	35	82.8
Ruhr 3	<i>AluJo</i>	<i>AluJb</i>	19	77.6
Ruhr 4	<i>AluSz</i>	<i>AluY</i>	25	75.8
Ruhr 5	<i>AluJo</i>	<i>AluJb</i>	19	77.6
Ruhr 6	Tigger4a	AT_rich	1 bp ins	–
Ruhr 7	<i>AluSp</i>	<i>AluSp</i>	8	87.9
Ruhr 9	<i>AluSx3</i>	<i>AluSz^c</i>	5	82.7
Ruhr 10	<i>AluSx3</i>	<i>AluSz^c</i>	5	82.7
Ruhr 11	<i>AluSx1</i>	<i>AluSz</i>	38	82.7
Ruhr 12	<i>AluSx</i>	<i>AluSx3</i>	9	77.4
Ruhr 13	<i>AluSz6</i>	<i>AluSp</i>	24	84.4
Ruhr 14	<i>AluJb</i>	<i>AluSz^c</i>	18	77.6
Ruhr 15	<i>AluJo</i>	<i>AluY</i>	22	79.9
Ruhr 16	<i>AluSx</i>	<i>AluSp</i>	20	79.1
Ruhr 17	–	–	3	–

Table 2. Continued

Subject	Left Breakpoint Repeat	Right Breakpoint Repeat	Microhomology (bp)	% Identity of Repeats ^b
Ruhr 18	<i>AluSz6</i>	<i>AluSp</i>	24	84.4
Ruhr 21	<i>AluY</i>	<i>AluSp</i>	33	83.2
Ruhr 23	<i>AluY</i>	<i>AluSz</i>	11	85.6
Ruhr 26 ^d	NA	NA	NA	NA
Ruhr 27	<i>AluY</i>	<i>AluSp</i>	complex	complex
Ruhr 28	–	L1M4	4	–
Ruhr 29	L1MC2	L1M5	0	–
Ruhr 31	<i>AluY^c</i>	<i>AluY</i>	5	90.7
Ruhr 32 ^d	NA	NA	NA	NA
Park 1	<i>AluSx1</i>	<i>AluSp</i>	7	80.7
Park 2	–	FLAM_C	3	–
Park 3	<i>AluY^c</i>	<i>AluSx^c</i>	8	81.1
Park 4	–	<i>AluSq</i>	4	–
A37	<i>AluY</i>	<i>AluY</i>	8	89.4
A38	<i>AluY</i>	<i>AluSx3</i>	complex	complex
A39	<i>AluSx^c</i>	<i>AluY</i>	26	81.7
Iwanaga	–	<i>AluSx3</i>	1	–
Mitne-Neto	–	L1M7	0	–
Miura	<i>AluSx1</i>	<i>AluJb</i>	9	77.1

Left, telomeric; right, centromeric; –, not applicable or no repeat present.

^aAll *Alu-Alu* and LINE-LINE pairs are in matching genomic orientation (both negative or both positive) (Table S1, Figure 2A), with the exception of Ruhr 29.

^bNumber of identical bases divided by smaller repeat length. Comparison by Needleman-Wunsch Global Alignment algorithm.

^cRepeat contains the consensus 13-nt sequence associated with meiotic recombination hotspots, some NAHR breakpoint regions, and bound in vitro by PRDM9.^{42–44} The *Alu* from which the inserted sequence in the complex A2 rearrangement derives contains this sequence.

^dBreakpoint unable to be sequenced (Ruhr 26) or failed breakpoint PCR (Ruhr 32).

in vitro by PRDM9, a protein with a role in meiotic homologous recombination.^{42–44} *Alus* are enriched for this motif. We analyzed sequence within or flanking *SPAST* (chr2: 32,280,000–32,412,000) and found 24 of these motifs, 23 of which are in or overlap *Alus* (Figure 4B, Table 3). This motif is present in one breakpoint *Alu* of ten *Alu*-mediated CNVs, at both breakpoint *Alus* of one CNV (Park 3), and in the *Alu* from which inserted breakpoint sequence is derived in one apparently complex rearrangement (A2) (Figure 4).

Twenty-eight CNVs are *Alu* mediated, unique, and noncomplex. Of these CNVs' 56 breakpoint *Alus*, 12 (21%) contain the 13-mer consensus motif. To investigate whether this represents an enrichment of the 13-mer motif in breakpoint *Alus* of *Alu*-mediated CNVs (and thus may be involved in their formation), we made the following comparisons to other groups of *Alus*. First, seven non-*Alu*-mediated CNVs have a single breakpoint in an *Alu*




Figure 4. The Consensus 13-mer, CCNCCNTNNCCNC, Associated with Meiotic Recombination/NAHR Hotspots Is Present at Breakpoint *Alu* of Some *Alu*-Mediated CNVs

(A) CNVs (black bars) displayed with breakpoint *Alu*s (pentagons; filled and intersected by a colored line if they contain the consensus 13-mer [CCNCCNTNNCCNC] associated with meiotic recombination/ NAHR hotspots^{42,43}). This motif is present at a single breakpoint *Alu* of ten *Alu*-mediated CNVs, at both breakpoint *Alu*s of one CNV (Park 3), and in the *Alu* from which inserted breakpoint sequence is derived in one apparently complex rearrangement (A2). Abbreviation: Dup, duplication.
 (B) All instances of the 13-mer (black arrowheads).
 (C) SINE elements (RepeatMasker track via UCSC Genome Browser).

(Figure 2, Table 2); of these, none contain the 13-mer (0%); this paucity was not significant ($p = 0.329$, two-tailed Fisher exact test). Second, there are 188 *Alu*s within and flanking *SPAST* (chr2: 32,280,000–32,412,000; Figure 4C); 23 of these contain the 13-mer (12%); this decrease is not significant ($p = 0.126$, two-tailed Fisher exact test).

Deletions Resulting in Chimeric Genes

Although 28 CNVs are purely intragenic, seven CNVs extend 5' of *SPAST*, and for 22 CNVs a breakpoint maps beyond the 3' end of the gene; of these CNVs overlapping *SPAST*, 17 affect additional genes (Figure 2A, Table 1). Two deletions extending beyond the 5' end of *SPAST* (BAB 3200 and Miura) have telomeric breakpoints in another gene, *DPY30* (MIM 612032). *DPY30* is in reverse genomic orientation with *SPAST*; thus, a chimeric *SPAST-DPY30* gene is less likely to result from these deletions. The effect of heterozygous loss of function of *DPY30* is unclear, as an association between *DPY30* and any human disease has not been described, although its ortholog appears to be developmentally important in *C. elegans* (reviewed by Miura et al.⁴⁰).

Thirteen deletions (and one duplication) that extend beyond the 3' end of *SPAST* have centromeric breakpoints in other genes (*SLC30A6* = 10 deletions; *NLRC4* [MIM 606831] and *TTC27* = 1 deletion each; *BIRC6* [MIM 605638] = 1 deletion and 1 duplication) (Figure 5). *SLC30A6*, *BIRC6*, and *TTC27* are in direct orientation with *SPAST*; thus, the 12 deletions of the 3' end of *SPAST*

and the 5' end of these genes form chimeric genes in these subjects' genomes (Figure 5A). Multiple transcript isoforms have been identified for *SLC30A6*, *BIRC6*, and *TTC27*; thus, multiple fusion transcripts incorporating 5' *SPAST* exons and 3' exons of these genes are possible in subjects with such deletions (Figure 5B). Eight of twelve deletions have at least one predicted in-frame transcript. The *SPAST_3* duplication is not anticipated to disrupt *SPAST* and thus is not likely to convey pathogenic changes to the spastin protein (consistent with this subject's unknown status for spastic paraplegia). However, it creates an additional *BIRC6:SPAST* chimeric gene, the predicted fusion transcript of which is in-frame (Figure 5C). RNA was not available from any of these deletion or duplication subjects to examine experimentally for fusion transcripts.

None of the genes potentially involved in a fusion transcript (*SLC30A6*, *BIRC6*, and *TTC27*), nor any of the other genes affected by deletions spanning beyond the 3' end of *SPAST* (*NLRC4*, *YIPF4*, *MIR558*, *MIR4765*, *LINC00486*, *LOC100271832*, *LTBP1* [MIM 150390], and *5S_rRNA*), is associated with Mendelian disease. Thus, the potential consequences to gene regulation or function of CNVs affecting these loci are unknown.

Deletion of *SPAST* Exon 17 Can Generate Fusion Transcripts with *SLC30A6*

Because *SLC30A6* is the nearest gene downstream of *SPAST*, *SPAST* deletions with 3' breakpoints in the 8 kb region between the two genes could potentially affect one or more *SLC30A6* regulatory regions and/or result in splicing

Table 3. 13-mer CCNCCNTNNCCNC Associated with Meiotic Recombination/NAHR Hotspots within and Flanking SPAST^a

Coordinate	Orientation	Within Alu?	Alu Used in CNV Breakpoint?
chr2: 32,290,968	negative	–	–
chr2: 32,292,376	positive	<i>AluSz</i>	Ruhr 9, Ruhr 10
chr2: 32,294,873	positive	<i>AluY</i>	–
chr2: 32,300,868	positive	<i>AluSz</i>	–
chr2: 32,303,490	positive	<i>AluSz6</i>	A2 (complex)
chr2: 32,311,592	negative	<i>AluSx</i>	–
chr2: 32,317,837	negative	<i>AluSx</i>	–
chr2: 32,323,295	negative	<i>AluJr</i>	–
chr2: 32,337,660	positive	<i>AluSg</i>	–
chr2: 32,339,234	negative	<i>AluJo</i>	–
chr2: 32,346,229	negative	<i>AluSx1</i> (overlaps)	–
chr2: 32,351,109	positive	<i>AluY</i>	Park 3, Ruhr 31, Spain 8
chr2: 32,355,085	negative	<i>AluJr</i> (overlaps)	–
chr2: 32,360,010	positive	<i>AluSx</i>	Park 3, JKF C
chr2: 32,371,388	negative	<i>AluJo</i>	–
chr2: 32,375,404	positive	<i>AluSc</i>	–
chr2: 32,378,630	positive	<i>AluSx1</i>	A3, A4, A5, A8, A9, SPAST_1
chr2: 32,378,906	negative	<i>AluSx</i>	A1, A39, BAB 3327
chr2: 32,394,608	negative	<i>AluY</i>	–
chr2: 32,398,678	positive	<i>AluSx3</i>	A6
chr2: 32,399,507	positive	<i>AluJo</i>	–
chr2: 32,402,087	positive	<i>AluSz</i>	Ruhr 14
chr2: 32,406,792	negative	<i>AluSx</i>	–
chr2: 32,411,515	negative	<i>AluSx1</i>	–

^aChr2: 32,280,000–32,412,000.

between the last remaining *SPAST* exon and *SLC30A6*. Seven such *SPAST* deletions exist among our data set, their 3' breakpoints mapping within 6.5 kb to <1 kb of *SLC30A6* (Figure 5). An additional seven deletions have 3' breakpoints within the final exon (exon 17) of *SPAST* (Figure 5).

Nervous system RNA was not available from these subjects; however, a lymphoblastoid cell line from one subject with a complete exon 17 deletion (BAB 3327) was obtained. cDNA was prepared from this cell line and from a healthy control individual, BAB 3099;⁴⁵ both blood-derived and lymphoblastoid-cell-line-derived DNA from the control individual is free of *SPAST* CNVs as determined by aCGH (Figure 1). Two PCRs of cDNA were performed, one with primers closely flanking the deletion (forward primer in exon 16 of *SPAST* and reverse primer in *SLC30A6* exon 2) and one with primers flanking a larger

area (forward primer in *SPAST* exon 12 and reverse primer in *SLC30A6* exon 7, the first constitutive exon of this gene) (Figure 6). A few faint fusion transcript bands were present in the control individual. However, abundant, robust fusion transcript bands were present in the *SPAST* deletion CNV subject (BAB 3327) (Figures 6A–6C). Sequencing of all PCR products confirmed splicing from *SPAST* to *SLC30A6* (Figure 6E), further indicating that deletion of *SPAST* exon 17 can alter the expression/transcript structure of a downstream gene.

Effect of a *SPAST* Exon 17 Deletion on *SLC30A6* Expression Level

The possibility exists that, by creating *SPAST:SLC30A6* fusion transcripts or disrupting *SLC30A6* upstream regulatory sequences, the *SPAST* exon 17 deletion in BAB 3327 may affect *SLC30A6* expression level.⁴⁶ qPCR indicated that the level of expression of *SLC30A6* in a BAB3327 lymphoblastoid cell line does deviate significantly from that of eight pooled control lymphoblastoid cell lines (50th centile versus controls, empirical cumulative distribution function) (Figure 6).

Discussion

SPAST CNVs: Diverse Sizes, Boundaries, and Exons Rearranged

We delineated breakpoint junctions for 49 *SPAST* CNVs and document extensive diversity of disease-associated rearrangements in this gene, even for CNVs affecting a given exon. By increasing the number of published, disease-causing *SPAST* CNVs with known breakpoints from 7 to 54, we provide a resource for evaluating the pathogenicity of CNVs in *SPAST* identified during the course of genomic testing. Predicted in-frame deletions of exons 4, 8, and 9 in individuals with SPG4 suggest that these exons are indispensable, and a pathogenic, predicted in-frame duplication of exon 9 (24 amino acids) reinforces the sensitivity of the spastin AAA (ATPase Associated with various cellular Activities) domain to mutation⁴⁷ (Figure S5). No *SPAST* exons have been demonstrated to be dispensable. However, exon 2 or 3 deletions have not been reported in persons with SPG4; thus, these in-frame exons may be candidates for exon skipping⁴⁸ for individuals with pathogenic point mutations in them.

The CNV allele size versus frequency spectrum is skewed toward rearrangements of modest size relative to *SPAST*. A skewing toward small CNVs is reminiscent of the overall distribution of CNVs in personal genomes.⁴⁹ It may also reflect the mechanism(s) of formation of *SPAST* CNVs, discussed below.

Alu Elements Destabilize *SPAST*, Leading to CNVs with Unique Properties

We found that more than two-thirds of *SPAST* CNVs have breakpoints in pairs of directly oriented *Alus*. Thus,




Figure 5. *SPAST* CNVs Extending into 3' Genes Create Chimeric Genes, and Deletions Involving the Final Exon of *SPAST* Might Create *SPAST:SLC30A6* Fusion Transcripts or Alter *SLC30A6* Expression

(A–C) Deletions extending into 3' genes.

(A) Fourteen CNVs (black bars) extend into genes 3' of *SPAST* (13 deletions, 1 duplication). Three of the downstream genes (*SLC30A6*, *BIRC6*, *TTC27*) are in direct orientation with *SPAST*; thus, *SPAST* deletions intersecting these 3' genes potentially yield chimeric genes.

(B) Potential fusion transcripts resulting from the deletions shown in (A) for which the 3' intersected gene is directly oriented with *SPAST*. Potential fusion transcripts are based only on known splice isoforms of the 3' genes and include all *SPAST* exons present, although other

(legend continued on next page)

Alu-mediated CNV formation is the predominant, but not exclusive, mechanism generating rearrangements in *SPAST*. The observed predominance of *Alu*-mediated CNVs suggests that the *Alu*-rich genomic architecture of *SPAST* (36% of the gene with segments of even higher *Alu* density;¹⁴ Figure 2B) renders this locus susceptible to a variety of genome rearrangements and may explain why an appreciable percentage of mutations causing *SPG4* are CNVs.

Alu-mediated CNVs in our cohort share properties with *Alu*-mediated CNVs at other disease loci, including the presence of breakpoint microhomology, rearrangement between different *Alu* family members, and small size (Table 4). We found that *Alu*-mediated CNVs in *SPAST* are smaller than non-*Alu*-mediated CNVs (which include the eight largest rearrangements in our cohort). This could reflect a “boundary” created by a zone of low *Alu* density near *SPAST*. Alternatively, it suggests a potential size preference or limit as a general feature of *Alu*-mediated CNV formation. Human-specific *Alu*-mediated CNVs²² are even smaller (median 468 bp, mean 806 bp; range 101–7,255 bp) than *Alu*-mediated CNVs in disease loci, potentially a contributing factor to their becoming fixed in a species.

Proposed Mechanisms Generating *Alu*-Mediated CNVs

The hypothesized mechanism for *Alu*-*Alu*-mediated CNV formation has been homologous recombination between nonallelic *Alus*, i.e., *Alu*-*Alu* recombination.^{20,50} The *SPAST* CNVs we report are generally consistent with this model: pairs of *Alus* are directly oriented and render a complete, hybrid *Alu* in the recombined genome; complex rearrangements are infrequent.⁴³ However, the short length (<300 bp) and low percent identity (<91%) shared by *Alus* within each pair may be insufficient to meet the presumed requirements of ectopic homologous recombination derived from observational studies of NAHR at LCRs.^{51,52} Furthermore, the three complex *Alu*-mediated CNVs are inconsistent with formation by NAHR unless a familial *Alu* polymorphism existed prior to the rearrangement. Some of the *Alus* at breakpoints of *Alu*-mediated CNVs contained the 13-nucleotide consensus motif enriched at meiotic recombination hotspots and at some LCRs involved in NAHR.^{42,43} Although intriguing, any enrichment of this consensus motif in breakpoint *Alus* of

Alu-mediated CNVs was not significant when compared to either *Alus* present at one breakpoint of non-*Alu*-mediated CNVs or to all *Alus* within and near *SPAST*. Finally, an analysis of previous studies at other loci (Table 4) demonstrates that moderate identity breakpoint *Alu* pairs and occasional complex events are general features of *Alu*-mediated CNVs. These findings may implicate an alternative non-homologous-recombination mechanism for *Alu*-mediated CNV formation.¹⁴

One alternative rearrangement mechanism may be microhomology-mediated DNA repair,⁵³ for example microhomology-mediated end joining (MMEJ) or fork stalling and template switching (FoSTeS)/microhomology-mediated break-induced replication (MMBIR). These mechanisms are consistent with the microhomology present at the breakpoints of *Alu*-mediated CNVs among our and others' data (Table 4). MMEJ may explain the predominance of deletions over duplications. FoSTeS/MMBIR may explain the occasional apparently complex *Alu*-mediated CNV.¹⁴

Another alternative mechanism may be single-strand annealing (SSA).^{54,55} This double-strand break (DSB) repair pathway involves the annealing of directly oriented repeats flanking the DSB after they are made single-stranded by 5' to 3' end resection. The removal of the 3' flaps and filling of gaps by DNA synthesis then results in a simple, small deletion. In a study of translocation mechanisms, Elliott et al.⁵⁶ induced double-stranded breaks adjacent to a human *Alu* element on each of two nonhomologous chromosomes in cultured mouse cells; when the *Alu* elements were identical, SSA was the predominant mechanism generating translocations between these chromosomes. However, when the *Alus* were only 80% identical, the frequency of SSA diminished such that NHEJ became the predominant translocation-generating mechanism. Similarly, in yeast, a decrease of identity between two 205 bp repeats flanking a DSB site from 100% to 97% decreased the rate of SSA by 6-fold.⁵⁷

Another potential contributing mechanism could be homeologous recombination, reduced-frequency recombination between substrates that are somewhat but not perfectly identical.^{58–60} This model is consistent with the low percent identity (75.8%–90.7%) shared by breakpoint *Alu* pairs in our study.⁶¹ In addition, in 33 of 39 (85%) *Alu*-*Alu* events in this study, the substrate pairs were from different *Alu* families. Whereas NAHR generates recurrent

splice variants are possible. Predicted in-frame splicing is shown in black, out-of-frame in red. The deletion intersecting *NLRC4* (Spain 6) is not shown, because this gene is oriented oppositely to *SPAST*.

(C) Potential fusion transcript resulting from the duplication in subject *SPAST_3*. This tandem, directly oriented duplication results in duplication of three genes (*SLC30A6*, *NLRC4*, *YIPF4*) and a potential in-frame transcript joining exons 1–46 of *BIRC6* with exons 2–17 of *SPAST*; the normal, diploid copy number of full-length *SPAST* and *BIRC6* are left intact.

(D and E) Deletions involving the final exon of *SPAST*.

(D) Deletions with 3' breakpoints in the intergenic space between *SPAST* and *SLC30A6* (top, “span exon 17”) or within the final exon of *SPAST* (exon 17) (bottom, “interrupt exon 17”). The former group of deletions may alter *SLC30A6* expression by eliminating upstream *SLC30A6* regulatory sequence (potential regulatory sequences shown by H3K27Ac track from UCSC), and both groups of CNVs may result in fusion transcripts with *SLC30A6* by eliminating splicing to *SPAST* exon 17.

(E) Potential fusion transcripts resulting from the deletions shown in (D). Potential fusion transcripts are based only on known splice isoforms of *SLC30A6* and include all *SPAST* exons present. Black, predicted in-frame; red, predicted out of frame.




Figure 6. A Deletion of *SPAST* Exon 17 Yields Multiple *SPAST:SLC30A6* Fusion Transcripts

(A–D) PCR primers (arrows above and below gene models in D) were designed to detect *SPAST:SLC30A6* fusion transcripts in cDNA from subject BAB 3327, who has a deletion encompassing *SPAST* exon 17 (black bar in D). One primer set (F1 and R1) closely flanks the deletion, and the other (F2 and R2) spans a greater distance to account for alternative splicing known to exist in *SLC30A6* (exon 7 is the first constitutive exon in this gene). PCR of cDNA (A) reveals multiple transcripts in BAB 3327 not present in the control individual (BAB 3099). The majority of bands (white arrows) were extracted and sequenced. One extracted band (blue arrow) failed sequencing. Four bands (gray arrows) required a second preparation/electrophoresis to be visualized, extracted, and sequenced (B and C, white arrows).

(legend continued on next page)

CNVs with high formation rates during meiosis,⁶² our data and others' (Table 4) demonstrate that *Alu*-mediated CNVs are mostly or entirely nonrecurrent; thus, the formation rate of any particular rearrangement is low, again consistent with homeologous recombination.⁶³ Although the probability of any one *Alu*-mediated CNV occurring is miniscule, with more than one million *Alus* in the genome, the cumulative ability of *Alus* to act as a recombination substrate and generate genomic rearrangements may be substantial.

SPAST deletions predominate over duplications. This suggests that, if formed by recombination, these events are most often intrachromatid. Because *Alus* in close linear proximity along the same chromatid are generally expected to be in close three-dimensional proximity,⁶⁴ and because three-dimensional proximity has been suggested to be important for generation of rearrangements,⁶⁵ then perhaps small size is a general feature of *Alu*-mediated CNVs that is facilitated by chromosomal conformation itself. Long-range interactions, chromatin compartments,⁶⁴ tethering of *Alus*, and genome reorganization during the cell cycle⁶⁶ could also shape the spatial relationships of *Alus* and thus their probability of acting as rearrangement substrates. If these CNVs are formed by replicative template switching, small rearrangement size would be consistent with the known tendency of this process to occur more frequently over short distances.

Deletions Can Result in Chimeric Genes and Fusion Transcripts

Almost half of the CNVs we report extend beyond the boundaries of *SPAST*, many of which interrupt other genes. Although none of these other genes is known to be associated with Mendelian disease, their disruption could have phenotypic consequences. Moreover, 12 deletions extending 3' of *SPAST* form chimeric genes that may yield fusion transcripts, also of unknown phenotypic consequence. Of note are the deletions forming chimeric genes between *SPAST* and *SLC30A6* (solute carrier family 30, member 6) encoding a zinc transporter, ZnT6. Zinc and zinc transporter (including ZnT6) dynamics have been described to be altered in the brains of humans with Alzheimer disease and rodent models of dementia.^{34,35,67} Thus, the possibility of *SPAST* CNVs dysregulating *SLC30A6* expression could potentially inform the clinical observation of comorbid spastic paraplegia and dementia.³¹ Neither RNA nor cells were available from any subjects with combined SPG4 and dementia.

Seven CNVs have 3' breakpoints within the intergenic region between *SPAST* and *SLC30A6*, and an additional seven have 3' breakpoints within the final exon of *SPAST*. The

former group could affect *SLC30A6* expression and all could potentially form fusion transcripts. We investigated this possibility experimentally using RNA from an available non-neuronal cell type (lymphoblastoid cell line) from one subject with a deletion encompassing the final exon of *SPAST* (exon 17). A few low-abundance fusion transcripts were present in a control individual, the significance of which is unknown. However, abundant and additional fusion transcripts were present in the *SPAST* deletion subject, indicating that a deletion of only an exon of *SPAST* can affect gene expression beyond the gene itself. The phenotypic consequence of this, if any, requires additional investigation.

The expression level of *SLC30A6* in lymphoblastoid cell line RNA from this individual does not deviate significantly from that of eight control lymphoblastoid cell lines. Whether or not *SLC30A6* expression is affected in this individual in neurons is unknown.

Summary

Molecular characterization of novel *SPAST* CNV alleles contributes to knowledge of pathogenic variants in this gene and provides insights into the importance of particular exons for spastin function. Our data suggest that the *Alu*-rich genomic architecture of *SPAST* predisposes to CNVs in this gene, contributing appreciably to its mutability and to SPG4 disease and potentially by a mechanism other than homologous recombination. Furthermore, these data allow the generation of hypotheses concerning *Alus* as a genome-destabilizing entity. We provide evidence that *Alu*-mediated rearrangements shape gene and genome structure and that the CNVs that are generated affect both *SPAST* and adjacent genes and extragenic regions. Thus, such CNVs can affect gene expression beyond *SPAST* itself, with potential phenotypic consequences.

Supplemental Data

Supplemental Data include Supplemental Methods, six figures, and three tables and can be found with this article online at <http://dx.doi.org/10.1016/j.ajhg.2014.06.014>.

Acknowledgments

The authors thank the Spastic Paraplegia Foundation, Sandy Wilcock, and Amy Breman for assistance with subject/sample recruitment. We thank Gladys Zapata and Paula Patricia Hernandez for transforming lymphoblasts and Chad Shaw, Claudia Fonseca, and Avinash Dharmadhikari for technical advice. We are grateful to the Spanish Familial Spastic Paraplegia Association (AEPEF) and the European Hereditary Spastic Paraplegia Federation (Euro-HSP) for their support and collaboration. P.M.B. and

(E) Sequencing of PCR products in (A)–(C) demonstrates a variety of *SPAST:SLC30A6* fusion transcript isoforms in BAB 3327, only some of which are present in the control individual (BAB 3099). Dots indicate predicted in-frame (green dots) or out-of-frame (red dots) transcripts. Reading frame is unclear for transcripts with no dot. PCR products were sequenced in both forward (F) and reverse (R) genomic orientation, although only one orientation may be shown.

(F) *SLC30A6* qPCR. In lymphoblastoid cell lines, overall level of expression of *SLC30A6* in BAB 3327 does not differ significantly from that of eight healthy controls (50th centile versus controls, empirical cumulative distribution function). Data plotted as mean \pm standard deviation.

Table 4. Properties of *Alu*-Mediated CNVs Derived from Large Studies of CNVs at Specific Loci

Study	Gene	Syndrome	CNVs Studied (Unique)	Dups CNVs	<i>Alu</i> -Mediated CNVs	Average Breakpoint <i>Alu</i> Pair % Identity (Range)	Average Breakpoint Microhomology (Range)	Complex <i>Alu</i> -Mediated CNVs	<i>Alu</i> -Alus in Pair from Same Family	CNV size Avg. (Range)	Some Repeats Used in More than One CNV?
Present	<i>SPAST</i>	Spastic paraplegia 4	57 (44)	4	39/57 (68%)	82.7% (75.8%–90.7%)	17 bp (5–38 bp)	3/39 (8%)	6/39 (15%)	19.0 kb (1.9–73 kb)	yes
Frank et al. ¹⁶	<i>VHL</i> (MIM 608537)	Von Hippel-Lindau syndrome	33 (32)	0	29/33 (88%)	not reported	16 bp (2–45 bp)	2/29 (7%)	15/29 (52%)	38.2 kb (0.8–249 kb)	yes
Kuiper et al. ⁶⁸	<i>EPCAM</i> (TACSTD1) (MIM 185535); upstream of <i>MSH2</i> (MIM 609309)	Lynch syndrome	45 (19)	NA ^a	45/45 (100%)	81% (75%–91%)	15 bp (3–32; one 0 bp)	2/19 (11%)	5/19 (26%)	11.1 kb ^b (2.4–23.8 kb)	yes

^aOnly deletions were studied.

^bDeletions affecting *MSH2* were specifically excluded, limiting the potential size of CNVs.

I.M.C. are fellows of the Baylor College of Medicine Medical Scientist Training Program (T32GM007330). P.M.B. is supported by grants from the Wintermann Foundation and the Baylor Research Advocates for Student Scientists. I.M.C. was supported by a fellowship from the National Institute of Neurological Disorders and Stroke (F31 NS083159). C.R.B. is an HHMI Fellow of the Damon Runyon Cancer Research Foundation (DRG 2155-13). This work was supported in part by the US National Institute of Neurological Disorders and Stroke (RO1NS058529 to J.R.L.), the US National Human Genome Research Institute/National Heart, Blood and Lung Institute (U54HG006542), and the Spanish Fondo de Investigaciones Sanitarias (PS09/01830). J.K.F. is supported by the Spastic Paraplegia Foundation, the U.S. National Institute of Neurological Disorders and Stroke (RO1NS0679700), the U.S. Department of Veterans Affairs (Merit Review 5I01CX000344), the Geriatric Research Education and Clinical Center AAVAMC, and the Paul and Lois Katzman Family. J.R.L. holds stock ownership in 23andMe, Inc. and Ion Torrent Systems, Inc., and is a coinventor on multiple United States and European patents related to molecular diagnostics. M.J.S. is a shareholder of Genomic Consulting, a company related to the application of genomics in medicine. The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from molecular genetic testing offered in the Medical Genetics Laboratories. I.D.K. and S.D.B. are employees of Quest Diagnostics.

Received: April 25, 2014

Accepted: June 30, 2014

Published: July 24, 2014

Web Resources

The URLs for data presented herein are as follows:

1000 Genomes, <http://browser.1000genomes.org>

Agilent eArray, <https://earray.chem.agilent.com>

dbSNP, <http://www.ncbi.nlm.nih.gov/projects/SNP/>

GeneReviews, Dürr, A., Tallaksen, C., and Depienne, C. (2012).

Spastic paraplegia 4, <http://www.ncbi.nlm.nih.gov/books/NBK1122>

International HapMap Project, <http://hapmap.ncbi.nlm.nih.gov/>

Online Mendelian Inheritance in Man (OMIM), <http://www.omim.org/>

RepeatMasker, <http://www.repeatmasker.org>

UCSC Genome Browser, <http://genome.ucsc.edu>

References

1. Wiszniewski, W., Hunter, J.V., Hanchard, N.A., Willer, J.R., Shaw, C., Tian, Q., Illner, A., Wang, X., Cheung, S.W., Patel, A., et al. (2013). *TM4SF20* ancestral deletion and susceptibility to a pediatric disorder of early language delay and cerebral white matter hyperintensities. *Am. J. Hum. Genet.* 93, 197–210.
2. Okamoto, Y., Goksungur, M.T., Pehlivan, D., Beck, C.R., Gonzaga-Jauregui, C., Muzny, D.M., Atik, M.M., Carvalho, C.M.B., Matur, Z., Bayraktar, S., et al. (2014). Exonic duplication CNV of *NDRG1* associated with autosomal-recessive HMSN-Lom/CMT4D. *Genet. Med.* 16, 386–394.
3. Benito-Sanz, S., Royo, J.L., Barroso, E., Paumard-Hernández, B., Barreda-Bonis, A.C., Liu, P., Gracia, R., Lupski, J.R., Campos-Barros, Á., Gómez-Skarmeta, J.L., and Heath, K.E. (2012). Identification of the first recurrent *PARI* deletion in Léry-Weill

- dyschondrosteosis and idiopathic short stature reveals the presence of a novel *SHOX* enhancer. *J. Med. Genet.* **49**, 442–450.
4. Hjeij, R., Lindstrand, A., Francis, R., Zariwala, M.A., Liu, X., Li, Y., Damerla, R., Dougherty, G.W., Abouhamed, M., Olbrich, H., et al. (2013). *ARMC4* mutations cause primary ciliary dyskinesia with randomization of left/right body asymmetry. *Am. J. Hum. Genet.* **93**, 357–367.
 5. Loureiro, J.L., Brandão, E., Ruano, L., Brandão, A.F., Lopes, A.M., Thieleke-Matos, C., Miller-Fleming, L., Cruz, V.T., Barbosa, M., Silveira, I., et al. (2013). Autosomal dominant spastic paraplegias: a review of 89 families resulting from a portuguese survey. *JAMA Neurol.* **70**, 481–487.
 6. Depienne, C., Fedirko, E., Forlani, S., Cazeneuve, C., Ribai, P., Feki, I., Tallaksen, C., Nguyen, K., Stankoff, B., Ruberg, M., et al. (2007). Exon deletions of *SPG4* are a frequent cause of hereditary spastic paraplegia. *J. Med. Genet.* **44**, 281–284.
 7. Vandebona, H., Kerr, N.P., Liang, C., and Sue, C.M. (2012). *SPAST* mutations in Australian patients with hereditary spastic paraplegia. *Intern. Med. J.* **42**, 1342–1347.
 8. McDermott, C.J., Burness, C.E., Kirby, J., Cox, L.E., Rao, D.G., Hewamadduma, C., Sharrack, B., Hadjivassiliou, M., Chinnery, P.F., Dalton, A., and Shaw, P.J.; UK and Irish HSP Consortium (2006). Clinical features of hereditary spastic paraplegia due to spastin mutation. *Neurology* **67**, 45–51.
 9. Álvarez, V., Sánchez-Ferrero, E., Beetz, C., Díaz, M., Alonso, B., Corao, A.I., Gámez, J., Esteban, J., Gonzalo, J.F., Pascual-Pascual, S.I., et al.; Group for the Study of the Genetics of Spastic Paraplegia (2010). Mutational spectrum of the *SPG4 (SPAST)* and *SPG3A (ATL1)* genes in Spanish patients with hereditary spastic paraplegia. *BMC Neurol.* **10**, 89.
 10. Sauter, S., Mitterski, B., Klimpe, S., Bönsch, D., Schöls, L., Visbeck, A., Papke, T., Hopf, H.C., Engel, W., Deufel, T., et al. (2002). Mutation analysis of the *spastin* gene (*SPG4*) in patients in Germany with autosomal dominant hereditary spastic paraplegia. *Hum. Mutat.* **20**, 127–132.
 11. Mitne-Neto, M., Kok, F., Beetz, C., Pessoa, A., Bueno, C., Graciani, Z., Martyn, M., Monteiro, C.B.M., Mitne, G., Hubert, P., et al. (2007). A multi-exonic *SPG4* duplication underlies sex-dependent penetrance of hereditary spastic paraplegia in a large Brazilian pedigree. *Eur. J. Hum. Genet.* **15**, 1276–1279.
 12. Zhang, F., Gu, W., Hurler, M.E., and Lupski, J.R. (2009). Copy number variation in human health, disease, and evolution. *Annu. Rev. Genomics Hum. Genet.* **10**, 451–481.
 13. Gu, W., Zhang, F., and Lupski, J.R. (2008). Mechanisms for human genomic rearrangements. *Pathogenetics* **1**, 4.
 14. Boone, P.M., Liu, P., Zhang, F., Carvalho, C.M.B., Towne, C.F., Batish, S.D., and Lupski, J.R. (2011). *Alu*-specific microhomology-mediated deletion of the final exon of *SPAST* in three unrelated subjects with hereditary spastic paraplegia. *Genet. Med.* **13**, 582–592.
 15. Deininger, P. (2011). *Alu* elements: know the SINES. *Genome Biol.* **12**, 236.
 16. Franke, G., Bausch, B., Hoffmann, M.M., Cybulla, M., Wilhelm, C., Kohlhase, J., Scherer, G., and Neumann, H.P.H. (2009). *Alu-Alu* recombination underlies the vast majority of large *VHL* germline deletions: Molecular characterization and genotype-phenotype correlations in *VHL* patients. *Hum. Mutat.* **30**, 776–786.
 17. Lehrman, M.A., Schneider, W.J., Südhof, T.C., Brown, M.S., Goldstein, J.L., and Russell, D.W. (1985). Mutation in LDL receptor: *Alu-Alu* recombination deletes exons encoding transmembrane and cytoplasmic domains. *Science* **227**, 140–146.
 18. de Smith, A.J., Walters, R.G., Coin, L.J.M., Steinfeld, I., Yakhini, Z., Sladek, R., Froguel, P., and Blakemore, A.I.F. (2008). Small deletion variants have stable breakpoints commonly associated with *alu* elements. *PLoS ONE* **3**, e3104.
 19. Mei, D., Lewis, R., Parrini, E., Lazarou, L.P., Marini, C., Pilz, D.T., and Guerrini, R. (2008). High frequency of genomic deletions—and a duplication—in the *LIS1* gene in lissencephaly: implications for molecular diagnosis. *J. Med. Genet.* **45**, 355–361.
 20. Deininger, P.L., and Batzer, M.A. (1999). *Alu* repeats and human disease. *Mol. Genet. Metab.* **67**, 183–193.
 21. Strout, M.P., Marcucci, G., Bloomfield, C.D., and Caligiuri, M.A. (1998). The partial tandem duplication of *ALL1 (MLL)* is consistently generated by *Alu*-mediated homologous recombination in acute myeloid leukemia. *Proc. Natl. Acad. Sci. USA* **95**, 2390–2395.
 22. Sen, S.K., Han, K., Wang, J., Lee, J., Wang, H., Callinan, P.A., Dyer, M., Cordaux, R., Liang, P., and Batzer, M.A. (2006). Human genomic deletions mediated by recombination between *Alu* elements. *Am. J. Hum. Genet.* **79**, 41–53.
 23. Babcock, M., Pavlicek, A., Spiteri, E., Kashork, C.D., Ioshikhes, I., Shaffer, L.G., Jurka, J., and Morrow, B.E. (2003). Shuffling of genes within low-copy repeats on 22q11 (LCR22) by *Alu*-mediated recombination events during evolution. *Genome Res.* **13**, 2519–2532.
 24. Szabó, Z., Levi-Minzi, S.A., Christiano, A.M., Struminger, C., Stoneking, M., Batzer, M.A., and Boyd, C.D. (1999). Sequential loss of two neighboring exons of the tropoelastin gene during primate evolution. *J. Mol. Evol.* **49**, 664–671.
 25. Batzer, M.A., and Deininger, P.L. (2002). *Alu* repeats and human genomic diversity. *Nat. Rev. Genet.* **3**, 370–379.
 26. Boone, P.M., Soens, Z.T., Campbell, I.M., Stankiewicz, P., Cheung, S.W., Patel, A., Beaudet, A.L., Plon, S.E., Shaw, C.A., McGuire, A.L., and Lupski, J.R. (2013). Incidental copy-number variants identified by routine genome testing in a clinical population. *Genet. Med.* **15**, 45–54.
 27. de Ligt, J., Boone, P.M., Pfundt, R., Vissers, L.E.L.M., Richmond, T., Geoghegan, J., O'Moore, K., de Leeuw, N., Shaw, C., Brunner, H.G., et al. (2013). Detection of clinically relevant copy number variants with whole-exome sequencing. *Hum. Mutat.* **34**, 1439–1448.
 28. Iwanaga, H., Tsujino, A., Shirabe, S., Eguchi, H., Fukushima, N., Niikawa, N., Yoshiura, K., and Eguchi, K. (2005). Large deletion involving the 5'-UTR in the spastin gene caused mild phenotype of autosomal dominant hereditary spastic paraplegia. *Am. J. Med. Genet. A.* **133A**, 13–17.
 29. Salinas, S., Proukakis, C., Crosby, A., and Warner, T.T. (2008). Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. *Lancet Neurol.* **7**, 1127–1138.
 30. Nielsen, J.E., Johnsen, B., Koefoed, P., Scheuer, K.H., Grønbech-Jensen, M., Law, I., Krabbe, K., Nørremølle, A., Eiberg, H., Søndergård, H., et al. (2004). Hereditary spastic paraplegia with cerebellar ataxia: a complex phenotype associated with a new *SPG4* gene mutation. *Eur. J. Neurol.* **11**, 817–824.
 31. Murphy, S., Gorman, G., Beetz, C., Byrne, P., Dytko, M., McMonagle, P., Kinsella, K., Farrell, M., and Hutchinson, M. (2009). Dementia in *SPG4* hereditary spastic paraplegia: clinical, genetic, and neuropathologic evidence. *Neurology* **73**, 378–384.

32. Ribai, P., Depienne, C., Fedirko, E., Jothy, A.-C., Viveweger, C., Hahn-Barma, V., Brice, A., and Durr, A. (2008). Mental deficiency in three families with *SPG4* spastic paraplegia. *Eur. J. Hum. Genet.* *16*, 97–104.
33. Erichsen, A.K., Inderhaug, E., Mattingsdal, M., Eiklid, K., and Tallaksen, C.M.E. (2007). Seven novel mutations and four exon deletions in a collection of Norwegian patients with *SPG4* hereditary spastic paraplegia. *Eur. J. Neurol.* *14*, 809–814.
34. Smith, J.L., Xiong, S., Markesbery, W.R., and Lovell, M.A. (2006). Altered expression of zinc transporters-4 and -6 in mild cognitive impairment, early and late Alzheimer's disease brain. *Neuroscience* *140*, 879–888.
35. Lovell, M.A., Smith, J.L., and Markesbery, W.R. (2006). Elevated zinc transporter-6 in mild cognitive impairment, Alzheimer disease, and pick disease. *J. Neuropathol. Exp. Neurol.* *65*, 489–498.
36. White, K.D., Ince, P.G., Lusher, M., Lindsey, J., Cookson, M., Bashir, R., Shaw, P.J., and Bushby, K.M. (2000). Clinical and pathologic findings in hereditary spastic paraparesis with spastin mutation. *Neurology* *55*, 89–94.
37. Gonzaga-Jauregui, C., Zhang, F., Towne, C.F., Batish, S.D., and Lupski, J.R. (2010). *GJB1/Connexin 32* whole gene deletions in patients with X-linked Charcot-Marie-Tooth disease. *Neurogenetics* *11*, 465–470.
38. Boone, P.M., Bacino, C.A., Shaw, C.A., Eng, P.A., Hixson, P.M., Pursley, A.N., Kang, S.-H.L., Yang, Y., Wiszniewska, J., Nowakowska, B.A., et al. (2010). Detection of clinically relevant exonic copy-number changes by array CGH. *Hum. Mutat.* *31*, 1326–1342.
39. Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Durbin, R.M., Handsaker, R.E., Kang, H.M., Marth, G.T., and McVean, G.A.; 1000 Genomes Project Consortium (2012). An integrated map of genetic variation from 1,092 human genomes. *Nature* *491*, 56–65.
40. Miura, S., Shibata, H., Kida, H., Noda, K., Toyama, T., Iwasaki, N., Iwaki, A., Ayabe, M., Aizawa, H., Taniwaki, T., and Fukumaki, Y. (2011). Partial *SPAST* and *DPY30* deletions in a Japanese spastic paraplegia type 4 family. *Neurogenetics* *12*, 25–31.
41. Sulek, A., Elert, E., Rajkiewicz, M., Zdzienicka, E., Stepniak, I., Krysa, W., and Zaremba, J. (2013). Screening for the hereditary spastic paraplegias *SPG4* and *SPG3A* with the multiplex ligation-dependent probe amplification technique in a large population of affected individuals. *Neurol. Sci.* *34*, 239–242.
42. Myers, S., Freeman, C., Auton, A., Donnelly, P., and McVean, G. (2008). A common sequence motif associated with recombination hot spots and genome instability in humans. *Nat. Genet.* *40*, 1124–1129.
43. Sasaki, M., Lange, J., and Keeney, S. (2010). Genome destabilization by homologous recombination in the germ line. *Nat. Rev. Mol. Cell Biol.* *11*, 182–195.
44. Baudat, F., Buard, J., Grey, C., Fledel-Alon, A., Ober, C., Przeworski, M., Coop, G., and de Massy, B. (2010). *PRDM9* is a major determinant of meiotic recombination hotspots in humans and mice. *Science* *327*, 836–840.
45. Liu, P., Erez, A., Nagamani, S.C.S., Dhar, S.U., Kolodziejska, K.E., Dharmadhikari, A.V., Cooper, M.L., Wiszniewska, J., Zhang, F., Withers, M.A., et al. (2011). Chromosome catastrophes involve replication mechanisms generating complex genomic rearrangements. *Cell* *146*, 889–903.
46. Ligtenberg, M.J.L., Kuiper, R.P., Chan, T.L., Goossens, M., Hebeda, K.M., Voorendt, M., Lee, T.Y.H., Bodmer, D., Hoenselaar, E., Hendriks-Cornelissen, S.J.B., et al. (2009). Heritable somatic methylation and inactivation of *MSH2* in families with Lynch syndrome due to deletion of the 3' exons of *TACSTD1*. *Nat. Genet.* *41*, 112–117.
47. Shoukier, M., Neesen, J., Sauter, S.M., Argyriou, L., Doerwald, N., Pantakani, D.V.K., and Mannan, A.U. (2009). Expansion of mutation spectrum, determination of mutation cluster regions and predictive structural classification of *SPAST* mutations in hereditary spastic paraplegia. *Eur. J. Hum. Genet.* *17*, 187–194.
48. Aartsma-Rus, A. (2012). Overview on DMD exon skipping. *Methods Mol. Biol.* *867*, 97–116.
49. Wheeler, D.A., Srinivasan, M., Egholm, M., Shen, Y., Chen, L., McGuire, A., He, W., Chen, Y.-J., Makhijani, V., Roth, G.T., et al. (2008). The complete genome of an individual by massively parallel DNA sequencing. *Nature* *452*, 872–876.
50. Lehrman, M.A., Russell, D.W., Goldstein, J.L., and Brown, M.S. (1987). Alu-Alu recombination deletes splice acceptor sites and produces secreted low density lipoprotein receptor in a subject with familial hypercholesterolemia. *J. Biol. Chem.* *262*, 3354–3361.
51. Reiter, L.T., Hastings, P.J., Nelis, E., De Jonghe, P., Van Broeckhoven, C., and Lupski, J.R. (1998). Human meiotic recombination products revealed by sequencing a hotspot for homologous strand exchange in multiple HNPP deletion patients. *Am. J. Hum. Genet.* *62*, 1023–1033.
52. Metzberg, A.B., Wurzer, G., Huisman, T.H.J., and Smithies, O. (1991). Homology requirements for unequal crossing over in humans. *Genetics* *128*, 143–161.
53. Ottaviani, D., LeCain, M., and Sheer, D. (2014). The role of microhomology in genomic structural variation. *Trends Genet.* *30*, 85–94.
54. Haber, J.E. (2006). Transpositions and translocations induced by site-specific double-strand breaks in budding yeast. *DNA Repair (Amst.)* *5*, 998–1009.
55. Pâques, F., and Haber, J.E. (1999). Multiple pathways of recombination induced by double-strand breaks in *Saccharomyces cerevisiae*. *Microbiol. Mol. Biol. Rev.* *63*, 349–404.
56. Elliott, B., Richardson, C., and Jasin, M. (2005). Chromosomal translocation mechanisms at intronic alu elements in mammalian cells. *Mol. Cell* *17*, 885–894.
57. Sugawara, N., Goldfarb, T., Studamire, B., Alani, E., and Haber, J.E. (2004). Heteroduplex rejection during single-strand annealing requires Sgs1 helicase and mismatch repair proteins Msh2 and Msh6 but not Pms1. *Proc. Natl. Acad. Sci. USA* *101*, 9315–9320.
58. Mézard, C., Pompon, D., and Nicolas, A. (1992). Recombination between similar but not identical DNA sequences during yeast transformation occurs within short stretches of identity. *Cell* *70*, 659–670.
59. Yang, D., and Waldman, A.S. (1997). Fine-resolution analysis of products of intrachromosomal homeologous recombination in mammalian cells. *Mol. Cell. Biol.* *17*, 3614–3628.
60. Bailis, A.M., and Rothstein, R. (1990). A defect in mismatch repair in *Saccharomyces cerevisiae* stimulates ectopic recombination between homeologous genes by an excision repair dependent process. *Genetics* *126*, 535–547.
61. Rossetti, L.C., Goodeve, A., Larripa, I.B., and De Brasi, C.D. (2004). Homeologous recombination between AluX-sequences as a cause of hemophilia. *Hum. Mutat.* *24*, 440.

62. Dittwald, P., Gambin, T., Szafranski, P., Li, J., Amato, S., Divon, M.Y., Rodríguez Rojas, L.X., Elton, L.E., Scott, D.A., Schaaf, C.P., et al. (2013). NAHR-mediated copy-number variants in a clinical population: mechanistic insights into both genomic disorders and Mendelizing traits. *Genome Res.* 23, 1395–1409.
63. Waldman, A.S., and Liskay, R.M. (1987). Differential effects of base-pair mismatch on intrachromosomal versus extrachromosomal recombination in mouse cells. *Proc. Natl. Acad. Sci. USA* 84, 5340–5344.
64. Lieberman-Aiden, E., van Berkum, N.L., Williams, L., Imakaev, M., Ragozy, T., Telling, A., Amit, I., Lajoie, B.R., Sabo, P.J., Dorschner, M.O., et al. (2009). Comprehensive mapping of long-range interactions reveals folding principles of the human genome. *Science* 326, 289–293.
65. Fudenberg, G., Getz, G., Meyerson, M., and Mirny, L.A. (2011). High order chromatin architecture shapes the landscape of chromosomal alterations in cancer. *Nat. Biotechnol.* 29, 1109–1113.
66. Naumova, N., Imakaev, M., Fudenberg, G., Zhan, Y., Lajoie, B.R., Mirny, L.A., and Dekker, J. (2013). Organization of the mitotic chromosome. *Science* 342, 948–953.
67. Bush, A.I. (2013). The metal theory of Alzheimer's disease. *J. Alzheimers Dis.* 33 (Suppl 1), S277–S281.
68. Kuiper, R.P., Vissers, L.E.L.M., Venkatachalam, R., Bodmer, D., Hoenselaar, E., Goossens, M., Haufe, A., Kamping, E., Niessen, R.C., Hogervorst, F.B.L., et al. (2011). Recurrence and variability of germline *EPCAM* deletions in Lynch syndrome. *Hum. Mutat.* 32, 407–414.

The American Journal of Human Genetics, Volume 95

Supplemental Data

**The *Alu*-Rich Genomic Architecture of *SPAST*
Predisposes to Diverse and Functionally Distinct
Disease-Associated CNV Alleles**

Philip M. Boone, Bo Yuan, Ian M. Campbell, Jennifer C. Scull, Marjorie A. Withers, Brett C. Baggett, Christine R. Beck, Christine J. Shaw, Pawel Stankiewicz, Paolo Moretti, Wendy E. Goodwin, Nichole Hein, John K. Fink, Moon-Woo Seong, Soo Hyun Seo, Sung Sup Park, Izabela D. Karbassi, Sat Dev Batish, Andrés Ordóñez-Ugalde, Beatriz Quintáns, María-Jesús Sobrido, Susanne Stemmler, and James R. Lupski




Figure S2. CNV breakpoint PCRs. Note that no PCR product was obtained for Ruhr 32. This may be a complex CNV.




Figure S2, cont'd.




Figure S2, cont'd.




Figure S2, cont'd.

A1

Reverse complement sequence

```

Chr2:32378859 CTTTAGGCTGGGCAAAGTGGCTCACGTCTGTAATCCAGCACCTTTGGGAGGCCAAGGTGGGCGGATCACCTGAGGTTAGG 32378937
|||||
A1 305 CTTTAGGCTGGGCAAAGTGGCTCACGTCTGTAATCCAGCACCTTTGGGAGGCCGAGACAGGCGGATCACA--AGGTTAGG 229
| |||||
chr2:32384360 TAATTGGCTGGGCGCGGTGGCTCACGCCTGTAATCCAGCACCTTTGGGAGGCCGAGACAGGCAGATCACA--AGGTCAGG 32384437
rs187211683* *rs4519572 rs4407291* *rs4530415

```

At underlined bases marked with "*", a known SNP exists that matches the patient sequence, potentially explaining the difference between the patient and reference genomes at that position. No other known SNPs underlie any differences (dbSNP135 via UCSC Genome Browser).




Figure S3. CNV breakpoint sequences. (Top) For each CNV, the “upstream” (telomeric, above) and “downstream” (centromeric, below) reference genomic sequences are aligned with sequence obtained from the breakpoint PCR product (middle). The direction in which the breakpoint PCR product was sequenced (forward vs. reverse) is noted. Blue, bold text indicates identity between the breakpoint sequence and one part of the reference genome; pink, bold text indicates “microhomology” (a short stretch of identity between the upstream and downstream genomic sequences flanking a CNV breakpoint). Known SNPs that could potentially alter interpretation are shown. Some breakpoints are complex and/or can be interpreted in multiple ways (see figure). (Bottom) Chromatogram of breakpoint PCR product sequence, with microhomology (if any) highlighted.

A6


Reverse complement sequence

Chr2:32372785 CTGCCTCCCGGGTTCACGCCATTCTCCTGCCTCAGCCTCCCTAGTAGCTGGGACTACAGG 32372844

A6 608 CTGCCTCCCGGGTTCACGCCATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGAAATAGAGG 549

Chr2:32398527 CTGCTTCCCTGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGAAATAGAGG 32398586

No known SNPs underlie any differences (dbSNP135 via UCSC Genome Browser).

**A8**

Reverse complement sequence

Chr2:32378537 CA-----C-CT-GCCTGGCTAATTTTGTATTTTAGTGGAGACGGGGTTTCACCATGTT 32378589

A8 511 CA-----C-CT-GCCTGGCTAATTTTGTATTTTAGTAGAGATGGGGTTTCTCCATGTT 459

Chr2:32381252 CATGCGCCACTACCCAGCTAA-TTTTGTATTTTAGTAGAGATGGGGTTTCTCCATGTT 32381310

No known SNPs underlie any differences (dbSNP135 via UCSC Genome Browser).





Figure S3, cont'd.

SPAST 1

Forward sequence

Chr2:32378515 AGCTGGGATTACAGGCACCTGCCTG-----GCTAATTTTGTATTTTAGTGGAGACGGGGTTTCACCATGTTGGCCAGGCTGGTCTCG 32378605
 KCL133376 510 AGCTGGGATTACAGGCACCTGCCTG-----GCTAATTTTGTATTTTAGTAGAGATGGGGTTTCTCCATGTTGGTCAGGCTGGTCTTG 600
 Chr2:32381237 AGCTGGGATTACAGGCATGCGCCACTACCCAGCTAA-TTTTGTATTTTAGTAGAGATGGGGTTTCTCCATGTTGGTCAGGCTGGTCTTG 32381326


No known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).

**SPAST 3**

Forward sequence

Chr2:32726526 TCCATTCGGGTTATGTGTAGAGGGTTTAGACAGCTATTATATATTCATTCTTCAGCAGTTTTGGAAAAAGTG 32726597
 KCL186204 938 TCCATTCGGGTTATGTGTAGAGGGTTTAGACAGCTATTTTTGTACTTTAGTCTTAATCCAGTGGTTGAAAGA 1009
 Chr2:32294329 TATCTATCTTAAATTTTCTTTAGGAGATTGAA-TATTTTTGTACTTTAGTCTTAATCCAGTGGTTGAAAGA 32294400

No known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).


**Figure S3, cont'd.**

Spain 5

Reverse complement sequence

Chr2:32282809 **CTCCTGACCTCAAGTGATCCACCTGTCTCGGCCTCCCAAAGTGCTGGGATTACAGG**CGTTAGCCACAGCATCCAGCCTTAAGCATG Chr2:32282894Spain 5 213 **CTCCTGACCTCAAGTGATCCACCTGTCTCGGCCTCCCAAAGTGCTGGGATTACAGGTATGACCCACTGCACCCAACCCATACTCAA** 128Chr2:32295360 CTCCTGACCTGAAGTGATCCGCCTGCCTCA**GCCTCCCAAAGTGCTGGGATTACAGGTATGACCCACTGCACCCAACCCATACTCAA** Chr2:32295445


No known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).

**Spain 6**

Reverse complement sequence

Chr2:32302017 **TCACTGCAACCTCTGTTTCCAGGTTCAA**ACGATTCTCCTGCCTCAGCCTCCCAAGTAGC Chr2:32302076Spain 6 204 **TCACTGCAACCTCTGTTTCCAGGTTCAA**AGCTGAGTATCTTCTACAATTTCCAGATGA 145chr2:32472132 CAAGTAAACAACAGTTAGGGTGGGAACGG**AGCTGAGTATCTTCTACAATTTCCAGATGA** Chr2:32472191

No known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).


**Figure S3, cont'd.**

Spain 9

Forward sequence

chr2:32340370 **TCATTAGACATTTAATACCAAGTTTGGCTT**ACCAG**TCTGTTTATATAATGCTGTATATTCATT** 32340435
 rs181046857*
 Spain 9 38 **TCATTAGACATTTAATACCAAGTTTGGCTT**ACCAG**GCTGGAGTACAGTGAATATTTAGTCTTTT** 103
 chr2:32345390 CCTTCTACTCCTGTCTCCCACTTTTTTCTC**ACCAG**GCTGGAGTACAGTGAATATTTAGTCTTTT 32345455

At underlined bases marked with "*", a known SNP exists that matches the patient sequence, potentially explaining the difference between the patient and reference genomes at that position. No other known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).

**JKF B**

Forward sequence

chr2:32371871 **TGCAGTAAGCCGAGCACTGCAGCCTGGGCA**ACAGAGCAAGACT**TGCTCTCAAAAAAAAAAAAAAAAAAAAAAAAAA** 32371944
 JKF B 226 **TGCAGTAAGCCGAGCACTGCAGCCTGGGCA**ACAGAGCAAGACT**CA**TCT**CAAAAAAAAAAAAAAAAAANNNNNNNN** 299
 chr2:32373830 AGATCGTGCCACTGCAGCCTCCAGCCTGGGCG**ACAGAGCAAGACT**CA**TCT**CAAAAAAAAAAAAAAAAA**TAGCTGGGC** 32373903
 *rs9677320 *Multiple SNPs

At underlined bases marked with "*", a known SNP exists that matches the patient sequence, potentially explaining the difference between the patient and reference genomes at that position. No other known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).

The low-complexity region 3' of the breakpoint (poly-A) renders the sequence flanking the breakpoint somewhat less certain than in other subjects. Thus, this breakpoint may be considered provisional. This position of the breakpoint coincides with the length of the breakpoint PCR product (Supplemental Fig. S4).





Figure S3, cont'd.

JKF C

Reverse complement sequence

Chr2:32359860 **GTTCAGCAATTC**CCACGTCAGCCTCC**CGAGTAGCTGGGATTACAGGCATGCGCCACCACGCC**CGGCTAATTTTGTAGTTTGTAGTACACA Chr2:32359954
 JKF C 376 **GTTCAGCAATTC**CCACGTCAGCCTCC**CGAGTAGCTGGGATTACAGGCATGCGCCACCACGCC**TGACTAATTTTGTATTTTATTAGAGATG 282
 Chr2:32353159 GTTCAAGCAATTCGCCACGTCAGCTTCCT**GAGTAGCTGGGATTACAGGCATGCGCCACCACGCC**TGACTAATTTTGTATTTTATTAGAGATG Chr2:32353253
 *rs188067254
 *rs216540

At underlined bases marked with "*", a known SNP exists that matches the patient sequence, potentially explaining the difference between the patient and reference genomes at that position. No other known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).

**Ruhr 3**

Forward sequence

chr2:32291741 aaaaaaaGTAGGTCATTTTGGCTGGGCAC**GGTGGCTCATGCCTGTAATCCAGCACTTTGGGAGGCTGAGGTGGTGG** chr2:32291819
 Ruhr 3 369 AAAAAAAGTAGGTCATTTTGGCTGGGCAC**GGTGGCTCATGCCTGTAATCCAGCACTTTGGGAGGCCAAGGCAGGTGG** 447
 chr2:32357157 TTTACTTTTAAGAAAGTTGAGGCTAGGTGT**GGTGGCTCATGCCTGTAATCCAGCACTTTGGGAGGCCAAGGCAGGTGG** chr2:32357235

No known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).





Figure S3, cont'd.

Ruhr 11

Reverse complement sequence

chr2:32308107 CACAGCTCACTGCAACCTCTGCCTCCCCG-GTCAAGTGATTCTCTGCCTCAGCCTCCCAAGTAGCTGATTACAGGTGCCGCCACCACAACCAGC 32308204
 rs148709324*
 Ruhr 11 422 CACAGCTCACTGCAACCTCTGCCTCCCCG-GTCAAGTGATTCTCTGCCTCAGCCTCCCAAGTAGCTGGGATTACAGGCATGTGCCACTATGCCCAGC 325
 chr2:32341601 CTTAGCTCACTGCAACCTCTGCCTCCAGAA TTC AAG TG ATT CT CT GC CT CAG C CT CCA AG TAG CT G GG ATT AC AG GC AT GT GCC ACT AT GCC CAG C 32341699

At underlined bases marked with "*", a known SNP exists that matches the patient sequence, potentially explaining the difference between the patient and reference genomes at that position. No other known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).

**Ruhr 12**

Reverse complement sequence

chr2:32274877 TTCTGTATTTTTAGTGGAGACGGAGTTTCTCCATGTTGGTCAGGCTGGTCAGAACTCCCGACCTCAGG 32274945
 Ruhr 12 205 TTCTGTATTTTTAGTGGAGACGGAGTTTCTCCATGTTGGCCAGACTGGTCACGAACTCCTGACCTCAGG 137
 chr2:32291212 TTTTGTATTTTTAGTAGAGATGGTGTTCACCATGTTGGCCAGACTGGTCACGAACTCCTGACCTCAGG 32291280

No known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).





Figure S3, cont'd.

Ruhr 15

Reverse complement sequence

chr2:32291761 GGCTGGGCACGGTGGCTCATGCCTGTAATCCAGCACTTTGGGAGGCTGAGGTGGGTGGATTGCTTGAGCCCAGGAGTTGA 32291842
 |||||
 Ruhr 15 266 GGCTGGGCACGGTGGCTCATGCCTGTAATCCAGCACTTTGGGAGGCTGAGGCAGGTGGATCACCTGAGGTCAGGAGTTCGA 185
 |||||
 chr2:32364615 GGCTGGGCACAGTGGCTCATGCCTGTAATCCAGCACTTTGGGAGGCTGAGGCAGGTGGATCACCTGAGGTCAGGAGTTCGA 32364696


No known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).

**Ruhr 16**

Reverse complement sequence

chr2:32338390 GTGATCTGCCCGCTCAGCCTCCAAAATGCTGGGATTACAGGCGTGAGCTACTGCACCCGGCCTAAAATTGATTAGTTT 32338469
 |||||
 Ruhr 16 241 GTGATCTGCCCGCTCAGCCTCCAAAATGCTGGGATTACAGGCGTGAGCCACCGTGCCCAAAGTTAATTTTTTTTAA 162
 |||||
 chr2:32340253 GTGATCCGCTGCCTCAGCCTCCAAAAGTACTGGGATTACAGGCGTGAGCCACCGTGCCCAAAGTTAAttttttttAAA 32340332

No known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).


**Figure S3, cont'd.**

Ruhr 21

Reverse complement sequence

chr2:32360273 **ACTGCAAGCTCCACCTCCTGGGTTACAGCCATTCTCTGCCTCAGCCTCCCGAGTAGCTGGGA**CTACAGGCGCCTGCCACCACGCCTGGCTAAT 32360366
 |||||
 Ruhr 21 283 **ACTGCAAGCTCCACCTCCTGGGTTACAGCCATTCTCTGCCTCAGCCTCCCGAGTAGCTGGGA****TTACAGGCATGCGCCACTACCCAG-CTAAT** 191
 |||||
 chr2:32381182 ACCACAACCTCCGCTCCAGGTTCAAGCA**ATTCTCTGCCTCAGCCTCCCGAGTAGCTGGGA****TTACAGGCATGCGCCACTACCCAG-CTAAT** 32381274


No known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).

**Ruhr 23**

Forward sequence

chr2:32372797 **TTCAGGCCATTCTCTGCCTCAGCCTCCCTAGTAGCTGGGA**CTACAGGCGCCCACCACCACGCCTGGCTAA 32372867
 |||||
 Ruhr 23 337 **TTCAGGCCATTCTCTGCCTCAGCCTCCCTAGTAGCTGGGA****TTACAGGCGCGTGCCACTACGCCCGGCTAA** 407
 |||||
 chr2:32390371 **TTCAGGCGATTCTCTGCCTCAGCCTCCAGAGTAGCTGGGA****TTACAGGCGCGTGCCACTACGCCCGGCTAA** 32390441

No known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).

**Ruhr 26**

Sequencing failed to identify the breakpoint sequence.

Figure S3, cont'd.

Ruhr 28


Reverse complement sequence

chr2:32288676 GAGGGGCCCGAGCCACCGACTGCAGGAGGAGAAGGGGTTGTGCTCCTGGCCGAGGAAGGAGAAA 32288739Ruhr 28 508 GAGGGGCCCGAGCCACCGACTGCAGGAGGAGAAGTGGTATCTCGTTGTGATTTGATTTGCATG 445

chr2:32305164 TTTTAAAATAATAGTCATCCTAAAGGGTATGAAGTGGTATCTCGTTGTGATTTGATTTGCATG 32305227

No known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).


SPAST transcription start site underlined.

**Ruhr 29**

Forward sequence

Chr2:32348551 AGTCCCAGTCAAACCCAGCCAGTTATTTTGTGGATACTGGCAAACTAAAGTTTATATGAAAAGGCAAAGACCTAGAACAGCCA 32348635Ruhr29 296 AGTCCCAGTCAAACCCAGCCAGTTATTTTGTGGATACTGGCACAATAGTCATCCTTCCCTTCTGATCTGCAGAGAGAGTTGT 380

Chr2:33632481 TATTTTAGGGTGTATACCTATGGGTGGAACACTTCATTTTATTCAATAGTCATCCTTCCCTTCTGATCTGCAGAGAGAGTTGT 33632565


**Figure S3, cont'd.**

Ruhr 31

Forward sequence

```
chr2:32350903 G C C C G G T T G G A G T G C A G T G G C G C A A T C T T G G C T C A A T A C A C G C T C C G C T C C G G G T T C A C G C C A T T T C C T G C C T C A G C C T C C T G A G T A G C T G G G A C G A 32351003
Ruhr 31 204 G C C C G G T T G G A G T G C A G T G G C G C A A T C T T G G C T C A A T A C A C G C T C C G C T C C G T G G G T T C A C G C C A T T C T C T G C C T C A G C C T C C C G A G T A G C T G G G A C T A 304
Chr2:32360238 G C C C G G C T G G A G T G C A G T G G T A C C A T C T C G G C T C A C T G C A A G C T C C A C C T C C T G G G T T C A C G C C A T T C T C T G C C T C A G C C T C C C G A G T A G C T G G G A C T A 32360338
```

No known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).

**Ruhr 32**


Breakpoint PCR failed to yield a product.

Park 1

Forward sequence

```
Chr2:32338700 T C T C G G C T T A C T G C A A C C T C C G C C T C C T G A G T T C A A G T G A T T C T C C T G C C T C A G C C T C C G A A G T A G C 32338766
Park_1 741 T C T C G G C T T A C T G C A A C C T C C G C C T C C T G A G T T C A A G C G A T T C T C A T G C C T C A A C C T C C C G A G T A G C 807
Chr2:32350358 T C T C G G C T C A C T G A A A C C T C C G C C T C C A G G G T T C A A G C G A T T C T C A T G C C T C A A C C T C C C G A G T A G C 32350424
```

No known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).

**Figure S3, cont'd.**

Park 2

Forward sequence


```

Chr2:32339676 AATCACAATGGTTTTACTTTTTCCCTTGTGAGAAAGTGGAGCTGTTCAAAAAGAAAAGACCCCTTAACACACACTA 32339751
Park_2      257 AATCACAATGGTTTTACTTTTTCCCTTGTGAGAAAGTGGAGTCCAGGAGTTCGACACCAGCCTGGGCAATGTAGTGA 312
Chr2:32347756 CCCAGCACTTTTCAGAGGCCAAGGCAGGAAGATGCTTGGAGTCCAGGAGTTCGACACCAGCCTGGGCAATGTAGTGA 32347831
                *rs12611678

```

At underlined bases marked with "*", a known SNP exists that matches the patient sequence, potentially explaining the difference between the patient and reference genomes at that position. No other known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).

The first nucleotide of *SPAST* exon 5 is underlined in red.

**Park 3**

Forward sequence

```

Chr2:32351019 ACGCCCGCTAAATTTTTTGTATTTTAGTAGAGACGGGTTTCATCGTGTAGCCAGGATGGTCTCGATCTCCTGACCTCGTGAT 32351104
Park_3      315 ACGCCCGCTAAATTTTTTGTATTTTAGTAGAGACGGGTTTCACCATGTTGGCCAGGATGGTCTTGAACCTCCGACCTCAGGTG 400
Chr2:32359920 ACGCCCGCTAA--TTTTTGTAGTTTGTAGTAGACACAAGGTTTCACCATGTTGGCCAGGCTGGTCTTGAACCTCCGACCTCAGGTG 32360003

```

It is unclear whether the underlined base represents complexity or a novel SNP.

No known SNPs underlie any differences (dbSNP137 via UCSC Genome Browser).




Figure S3, cont'd.




Figure S3, cont'd.




Figure S4. Breakpoint *Alu* pairs aligned for each non-complex, *Alu*-mediated CNV. The telomeric *Alu* is on top in each pairing. Heat map shading depicts a 10 bp sliding window of identity. Microhomology/crossover spots are flanked by black lines; these occupy various positions within the *Alu* pairs.




Figure S5. Pathogenic in-frame deletions and duplication of *SPAST* exons. Deletions (green) of exons 4, 8, and 9 of *SPAST*, predicted to be in-frame, in SPG4 patients suggests that these exons are indispensable. A pathogenic, predicted in-frame duplication (red) of exon 9 (24 amino acids) reinforces the sensitivity to mutation of spastin's AAA (ATPase associated with various cellular activities) domain.¹ Reported, predicted in-frame multi-exon deletions (green) are also shown. Shaded *SPAST* exons are predicted to alter reading frame when deleted or duplicated whereas unshaded exons are multiples of 3 nucleotides and thus are predicted to preserve reading frame. Data are drawn from all published *SPAST* CNVs whether breakpoint sequences were assessed or not.²⁻⁶ Domain map from ¹. TM, transmembrane; MIT (microtubule interacting and trafficking); MTBD (microtubule binding domain); *, alternatively spliced exon.

Ruhr 9, Ruhr 10 - Haplotype in 1000 Genomes: 852/1984 (42.9%)

SNP	rs13017189	rs660393	rs572946	rs13000753	rs34460762	rs13024004	rs652978	rs201350097	rs62142107	rs6758024	rs10084410	rs78871913	rs10084280	rs17011801	rs113080319
Position (chr2)	32281280	32281509	32281510	32282297	32282340	32282362	32286411	32286411	32294435	32294486	32296099	32296134	32297984	32298072	32298273
Ref/minor allele; MAF	A/G; 47.523%	C/A; 42.811%	T/G; 2.657%	T/C; 45.263%	G/C; 10.073%	A/G; 45.359%	A/T; 47.965%	-/T; 42.883%	T/A; 5.637%	G/C; 44.538%	A/G; 3.972%	G/C; 1.218%	G/A; 5.680%	A/T; 32.088%	T/A; 1.330%
Ruhr 9	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt
Ruhr 10	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt

Ruhr 3, Ruhr 5 - Haplotype in 1000 Genomes: 1049/1984 (52.9%)

SNP	rs115440025	rs112067196	rs3769603	rs6725068	rs3830711
Position (chr2)	32360726	32360852	32360887	32360930	32362084
Ref/minor allele; MAF	T/C; 1.131%	A/G; 1.330%	C/A; 43.230%	C/T; 3.715%	-/ATAT; 36.239%
Ruhr 3	Wt	Wt	Wt	Wt	Wt
Ruhr 5	Wt	Wt	Wt	Wt	Wt

Ruhr 13, Ruhr 18 - Haplotype in 1000 Genomes: 102/1984 (5.1%)

dbSNP 138	rs12617289	rs12617290	rs7574000	rs116766118	rs13022197	rs60386495	rs150295812	rs11681731	rs6716179	rs72796871	rs72863940	rs75497994	rs139405008	rs12465351	rs7581432	rs7588883
Position (chr2)	32341399	32341408	32342888	32342989	32343167	32345123	32345168	32345325	32393076	32393157	32394674	32394704	32394747	32394905	32395315	32397267
Ref/minor allele; MAF	A/G; 46.481%	A/G; 45.480%	A/C; 30.769%	T/G; 1.436%	T/A; 44.401%	C/T; 10.046%	C/G; 1.377%	A/T; 46.460%	C/A; 50.425%	G/A; 4.003%	C/T; 45.163%	C/T; 5.440%	C/T; 1.148%	G/C; 50.601%	A/G; 50.397%	A/G; 52.168%
Ruhr 13	G	G	Wt	Wt	A	T	Wt	T	A	Wt	T	T	Wt	C	G	G
Ruhr 18	G	G	Wt	Wt	A	T	Wt	T	A	Wt	T	T	Wt	C	G	G

A1, A39, BAB 3327 - Haplotype in 1000 Genomes: 709/1984 (35.7%)

dbSNP 138	rs7572964	rs11694630	rs148193979	rs11678119	rs72796867	rs2280973	rs13425665	rs72097810	rs4952209	rs10208246	rs13429391
Position (chr2)	32372096	32376201	32376274	32376303	32376367	32378604	32385711	32385896	32386033	32386659	32386803
Ref/minor allele; MAF	A/T; 41.900%	G/A; 42.524%	A/C; 4.499%	T/C; 44.248%	T/C; 1.131%	C/A; 45.317%	C/A; 1.690%	AAG/-; 49.725%	G/C; 51.645%	G/A; 41.323%	C/T; 8.265%
A1	T	A	Wt	C	Wt	Wt	Wt	-	C	Wt	Wt
A39	T	A	Wt	C	Wt	Wt	Wt	-	C	Wt	Wt
BAB 3327	T	A	Wt	C	Wt	Wt	Wt	-	C	Wt	Wt

A4, A8, A9, SPAST 1 - Haplotype in 1000 Genomes: 895/1984 (45.1%)

dbSNP 138	rs2886393	rs7572964	rs11694630	rs148193979	rs11678119	rs72796867	rs12712326	rs111261438	rs13425665	rs72097810
Position (chr2)	32371562	32372096	32376201	32376274	32376303	32376367	32384194	32384269	32385711	32385898
Ref/minor allele; MAF	G/C; 43.046%	A/T; 41.900%	G/A; 42.524%	A/C; 4.499%	T/C; 44.248%	T/C; 1.131%	C/G; 9.817%	G/A; 2.570%	C/A; 1.690%	AAG/-; 49.725%
A4	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt
A8	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt
A9	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt	Wt
SPAST_1	*	*	*	*	*	*	*	*	*	*

Figure S6. SNPs flanking identical CNVs found in multiple individuals. To identify whether identical CNVs occurred on the same haplotype (i.e. no specific evidence for recurrent CNV formation) or different haplotype (i.e. suggests recurrence), common SNPs

(dbSNP 138 allele frequency $\geq 1\%$) flanking the CNVs were genotyped. No flanking SNPs differ among individuals sharing the same CNV, thus failing to provide evidence for recurrence. Note that some SNPs differ between individuals A1/A39/BAB3327 and individuals A4/A8/A9, indicating that *SPAST* CNVs have occurred on different haplotypes, a positive control of our method. SNPs are listed in genomic order. The empty space in each box indicates the location of the CNV. Reference alleles are listed as “Wt” and shaded in lavender. Non-reference alleles are shaded in blue. MAF, minor allele frequency (dbSNP 138). **SPAST* 1 SNPs could not be analyzed owing to failure at the PCR stage. PCR and raw sequencing data are not shown.

Supplemental Tables

Breakpoint PCR Primers ^a	
Primer name	Sequence (5' to 3')
A1 F1	TTTTTCTATTGCCTGGACTCTGTGAACCTATC
A1 R2	CTATCCACCATGTGAATAACTGCCTCAATCT
A2 F1	GGTGAAGAATATGTCTGCCAGTGAGGTATAGT
A2 R1	GGTCTCGTGAAAATTATATTCTGGTAGGGAAG
A3 F1	TATTCTTCTACACTTTGGCCTTTAGGAAGAGG
A3 R1	CAAATGAATGAGTGAGTGAGTGTGGATGTGT
A4 F1, A8 F1, A9 F1	TATTCTTCTACACTTTGGCCTTTAGGAAGAGG
A4 R1, A8 R1, A9 R1	GTTGAGCTGGAACCACATAGTCCCTTTAATATG
A5 F1	TATTCTTCTACACTTTGGCCTTTAGGAAGAGG
A5 R1	GAATAGTTCAGAGGAGAGTTGTTCAAGAGA
A6 F1	GTAGATCATTGTACTTGGTTTTGCCCTTCAAC
A6 R1	TTATTACACCAAAGAGCAGTATCTTCCAGGAC
A10 F1	TGATGCTCTCAGGTATGCACTCAGATTATTAG
A10 R1	GACTACTCAAGATACCTATCCCTTCCCTACA
BAB 3200 F1	AGCAATGCCTAAGAACTCCTATAACTCCTGT
BAB 3200 R1	AAACCAACTCCTCGGTGGTAAAAATGAAAG
BAB 3327 F1	TTTTTCTATTGCCTGGACTCTGTGAACCTATC
BAB 3327 R2	CTATCCACCATGTGAATAACTGCCTCAATCT
BAB 5112 F1	CTCTGTTGCATAGAGAAGATGCAACCAAGTTT
BAB 5112 R1	GTTTGTGTACTGCCTGGCTGCTATCTATTACT
SPAST 1 F1	ATATAGTGCTTATGGGGTTTTCTTGGTGGGG
SPAST 1 R1	GCTGGAACCACATAGTCCCTTTAATATGATTAGCC
SPAST 3 F1	TTATTGGTGAGGACTTCTGTTTAGGGGCTTCA
SPAST 3 R1	AATGGCTATCACAGGTTTTCAGTCTTCCAAGA
Spain 1 F1	GACTCTCCATTTCTTAGGTTCTCTGACATCTG
Spain 1 R1, Spain 7 R1	TTTGCTCACAGAGTTATGACCATTCTGCATAC
Spain 2 F1	CAGAGTACTTGTAAATGGGTGCAACTAATAGGC
Spain 2 R1	TCCTTTTCTCTATCCAACTCTCAGCACAT
Spain 3 F1	CCACACTTGTAATCTCATACAGCAGTTCTCAT
Spain 3 R1	GTTTACCATCTAATCACAGTGAGCATCTGAAC
Spain 4 F1	CTAACTGAGGCTTGTTCCTTAGTGGACAGC
Spain 4 R1	CCAGAGTCTTCCCTTCAAAGACACCTATTAT
Spain 5 R1	CAGAGCTGTACAAATTAAGTGGCCTCCAAT
Spain 6 F1, Spain 8 F1	GGTGAACATATGAGAGAATTAATCAGGGGCTAT
Spain 6 R1	TATACGCAGGTTAAGCTTGTCTTCAGCAAATC
Spain 7 F1	CAGCGAGAGAACTTGATTTTATCAGTACACC
Spain 8 R1	GCTGCCCATAGCTTTAAAGGAAACACATAATC
Spain 9 F1	TTAACACACACTAGTAATTCAGTCCCTCGTTC
Spain 9 R1	TGAAGGATGAATATCTAGAAAGTCCAAGAGG
JKF B F1	ATTACCAGTAACACCTCCCGTAGTGAATAGG
JKF B R1	TATCTGTGTTAACAGTTCACGTGCCCTCAAC
JKF C F1	CACACCGTCTTCAAATGTAAAGTTTGGTC
JKF C R1	GGAAACAGAGCACTCACGTATTTTGAAGTT
Ruhr 3 F1, Ruhr 5 F1	TTCATTCATAGTGTCTGTCTCTACTGCCAACT
Ruhr 3 R1, Ruhr 5 R1	AGTTCCTCCCAAAGCTTTCTCAGGATAGAT
Ruhr 4 F1, Spain 5 F1	GCGCTTCAGGGGCTAACAAATATACTTATTTT
Ruhr 4 R1	CAGTGATATCCCCCTTTGCTTTACTATATTCC
Ruhr 6 F1	TCTTACAGTATAGTCACTGGCAGTTTCCCTCT
Ruhr 6 R1	GCTGTTCCACTAAGAAACAAGACCTCAGTTAG
Ruhr 7 F1	CAAGGAAGAATATACTGGTCCCTTTTGTGAG

Table S2. Primer sequences.

Ruhr 7 R1, Ruhr 21 R1	GTTGAGCTGGAACCACATAGTCCTTTAATATG
Ruhr 9 F1, Ruhr 10 F1, Ruhr 28 F1	AAGAGACTCGTTCCAGTTACTTTCTATTTCG
Ruhr 9 R1, Ruhr 10 R1	GATACTGAAAGATTTAAGTCACCAGCCTGAGA
Ruhr 11 F1	AATAACCATCCTAATGGGCTTGATATGGTC
Ruhr 11 R1	AGTGAAATAACTGTGACCCAGAAGTGAGTCTT
Ruhr 12 F1	CAAGACTGTTGTTTAAAATGTGCTCCCCTA
Ruhr 12 R1	CCTTAATTTCTCCTTTTATCCTACCTCCCAAC
Ruhr 13 F1, Ruhr 18 F1	CCTCTTGGACCTTCTAGATATTCATCCTTCA
Ruhr 13 R1	AGGGCTGTGAGTTAATGAAGGTGATAATCTG
Ruhr 14 F1	GGTCCTATCCGAGGTAGGTATACAAGAGCTTA
Ruhr 14 R1	CCAGAGTCTTCTCTTCAAAGACACCTATTAT
Ruhr 15 F1	TTCAATTCATAGTGTCTGTCTCTACTGCCAACT
Ruhr 15 R1	CTATGAAACAAGAGCCCAAGTGAATGTAAGAG
Ruhr 16 F1	GGCCACTCTAATTTGCTGACTGACTTAACAT
Ruhr 16 R1	CCCTTGTTAGAAATCATGACAAAACCTCTAGG
Ruhr 17 R1	GTTTGGCATTCCAATCACCTGTAGTTAAGAC
Ruhr 18 R1	CCAGATCTGTCTAAACCAAGCTTATTTCAT
Ruhr 21 F1	ATCTATCCTGAGAAAGCTTTTGGGAGGAAT
Ruhr 23 F1, Ruhr 27 F1	GTTGAACATTGTTTTTGGGCAGTATGCAAG
Ruhr 23 R1	GGACCAATAAGATAAACCGAATCAGCTACAG
Ruhr 26 F1	GTTATGTGCGTCTTTTGTGTTTCCCTATC
Ruhr 26 R1	TATCTGTGTTAACAGTTCAGTGTCCCTCAAC
Ruhr 27 R1	GAATAGTTCCAGAAGGAGAGTTGTTCAAGAGA
Ruhr 28 R2	CTTTAACATTAGCTCCCAACAGTCCCTAGTTT
Ruhr 29 F2	CATCATAACCACACCTTCTACTCCTGTCTC
Ruhr 29 R2	CAAATATGATGTAAGGCCCCAGTCAGTCTTC
Ruhr 31 F1, Ruhr 17 F1	TAAAGTGTAGGTGAGAtgttttcagctctggag
Ruhr 31 R1	CACCAAAGTAATGAGTCATGAGGTCTGTGATA
Ruhr 32 F1	AGTGCTGATGTTATAATCCAAGCCCAATG
Ruhr 32 R1	GGGTCAATGGACTTCTTGTGTTTACATAACAG
Ruhr 32 F2	AAACTAGGGACTGTTGGGAGCTAATGTTAAAG
Ruhr 32 R2	GATTAAGGCATACTATCTCCAGAGGCTTCATT
Park 1 F1, Park 2 F1	TTGGCCACTCTAATTTGCTGACTGACTTAACA
Park 1 R1, Park 2 R1	TTTTTCAGTAGCATCTTCCCAAACAGAGCTGC
Park 3 F1	CCTTAGCTCCATCATACCACACACCTTCTACT
Park 3 R1	ACTTGCGCTATTAAGAACACCGTGAAAAGTCA
Park 4 F1	TATCTGGCACCACATCTCTGAAAAGCTCCAAT
Park 4 R1	CTCTTTTCTGTTTCACTCATCAGGTCAGCAGT
Long range Ctrl F	CTAGAAGGAACCTAGATAGGTCAAGCCTCTGC
Long range Ctrl R	AGAGGAGCTTCAGATGCTGGAAAGCTAGAG
cDNA PCR primers	
Primer name	Sequence (5' to 3')
SPAST exon 16 F1	CTAAAACCAGAACAGGTGAAGAA
SLC30A6 exon 2 R1	TCAGCTGCTACAAGTCTAAATTC
SPAST exon 12 F1	CAGTCTGCTGGAGATGACAGA
SLC30A6 exon 7 R1	GGCAAATACAGCCAGGACTT
External pos ctrl (KDM4C exon 18) F	CTGCATCCAGTGTTCCTACG
External pos ctrl (KDM4C exon 19) R	CCTCAGGAAATGTGTCTCTGC
Haplotyping PCR primers	
Primer name	Sequence (5' to 3')
Ruhr 9-10 Haplo F1	TCTAGAATCTCTCGAATGGAAGTCTGAAGAG
Ruhr 9-10 R1	GATACTGAAAGATTTAAGTCACCAGCCTGAGA
Ruhr 9-10 Haplo R1	CTGTTTAAATACCTCTCGTTCTTCCCATATC
Ruhr 9-10 F1	AAGAGACTCGTTTCCAGTTACTTTCTATTTCG
Ruhr 3-5 Haplo F1	GCAGTACTGGCGGGGAATAATTAAGTAAAA
Ruhr 3-5 R1	AGTTCCCTCCCAAAGCTTCTCAGGATAGAT
Ruhr 3-5 Haplo R1	GATAGGGAAAACAAAAGGACGCCAACATAACAC
Ruhr 3-5 F1	TTCAATTCATAGTGTCTGTCTCTACTGCCAACT

Table S2, cont'd.

Ruhr 13-18 Haplo F1	CCTACCACTCATAAGGTATTCTGGGACAGTAA
Ruhr 13 R1	AGGGCTGTGAGTTAATGAAGGTGTATAATCTG
Ruhr 13-18 Haplo R1	GAATAGTTCCAGAAGGAGAGTTGTTCAAGAGA
Ruhr 13 F1	CCTCTTGGACCTTCTAGATATTCATCCTTCA
A1-A39-BAB3327 Haplo F1	GCTGCTGGAGCTTAAATCTTGTTTCAGTTAG
A1-A39-BAB3327 R1 (A1 R2)	CTATCCACCATGTGAATAACTGCCTCAATCT
A1-A39-BAB3327 Haplo R1	GGGACCAATAAGATAAACCAGATCAGCTAC
A1-A39-BAB3321 F1 (A1 F1)	TTTTTCTATTGGCTGGACTCTGTGAACCTATC
A4-8-9 Haplo F1	GCTGGAGCTTAAATCTTGTTTCAGTTAGTGGAT
A4-8-9 R1	GTTGAGCTGGAACCACATAGTCTTTAATATG
A4-8-9 Haplo R1	TTCAGCTCTTCCATCCCAGTGTTCATCTTAC
A4-8-9 F1	TATCTTCTACACTTTGGCCTTTAGGAAGAGG
Haplotyping sequencing primers	
Primer name	Sequence (5' to 3')
Ruhr 9-10 Haplo Seq L F1	TGTCCTGAAAGTTCTTACAAGCT
Ruhr 9-10 Haplo Seq L R1	AGGAGAGAACAGCAGTGACA
Ruhr 9-10 Haplo Seq L R2	TGACCTACTCCCTGTTTCCC
Ruhr 9-10 Haplo Seq R F1	CAGAAGATGAGGATGGAGGGT
Ruhr 9-10 Haplo Seq R R1	TGACCCCTTTAGCCCTTTAAACT
Ruhr 9-10 Haplo Seq R R2	AGGGAATGGCAGTGCATGAT
Ruhr 3-5 Haplo Seq L F1	ATGTTTGTATGAATGGATTGCGT
Ruhr 3-5 Haplo Seq L R1	GCAACCGTTTTAATTCTCCCC
Ruhr 3-5 Haplo Seq L R2	ACGCAATCCATTCATCAAACAT
Ruhr 3-5 Haplo Seq R F1	GAAGAGAAGGGGAGCACGAT
Ruhr 3-5 Haplo Seq R R1	TGTTGAAAATCTAGCACACAGGA
Ruhr 3-5 Haplo Seq R F2	CTGGGAATGTCTCAAGGGGT
Ruhr 13-18 Haplo L F1	CTTCCTTCTCTGAGGCCTGA
Ruhr 13-18 Haplo L R1	ATAATGCACCCACCACAACG
Ruhr 13-18 Haplo L R2	AGTGGGAGGACAGGAGTAGA
Ruhr 13-18 Haplo R R1	TCACTGGGAGAAAAATATAAGCCA
Ruhr 13-18 Haplo R F1	GGCCACCAATGTAAACCTTCT
Ruhr 13-18 Haplo R F2	TGAAGGGAGTTGAAGATAAAGGG
A1-39 BAB3327 Haplo L R1	GCAGTTGAAATTTGTTGAAGGGC
A1-39 BAB3327 Haplo L R2	CTTGTGTTTACGTCTCATCCCA
A1-39 BAB3327 Haplo L R3	TAGGTTTACAGAGTCCAGGC
A1-39 BAB3327 Haplo R R1	ACAGTTCAGGAAGGAGGAAGG
A1-39 BAB3327 Haplo R R2	TACCATCTCTGTGACACCC
A 4-8-9 Haplo L R1	GCAGTTGAAATTTGTTGAAGGGC
A 4-8-9 Haplo L R2	CTTGTGTTTACGTCTCATCCCA
A 4-8-9 Haplo L F1	GCTGGAGCTTAAATCTTGTTTCAGTTAGTGGAT
A 4-8-9 Haplo R R1	TTCAGCTCTTCCATCCCAGTGTTCATCTTAC
A 4-8-9 Haplo R F1	CAGATGCACAAGTGACCTCT
A 4-8-9 Haplo R R2	AGAGGTCACTTGTGCATCTG

^aPrimers used exclusively for breakpoint sequencing are available upon request.

Table S2, cont'd.

STR Marker	AMEL	CSF1PO	D13S317	D16S539	D18S51	D19S433	D21S11	D2S1338	D3S1358	D5S818	D7S820	D8S1179	FGA	TH01	TPOX	vWA
Dye	R	B	G	G	Y	Y	B	G	G	R	B	B	R	G	Y	Y
Ruhr 9	X/Y	11/12	11/11	9/14	14/18	13/14.2	28/30	20/22	18/18	11/12	8/10	12/13	18/24	9.3/9.3	8/8	15/16
Ruhr 10	X/Y	10/10	11/12	10/13	13/18	10/14	30/30.2	17/19	15/16	11/13	8/11	12/17	19/22	7/8	8/8	16/16
Ruhr 3	X/Y	12/12	8/8	12/13	11/13	13/14	29/32	23/24	16/19	11/13	10/12	10/14	21/21	6/9.3	8/8	17/19
Ruhr 5	X/Y	10/11	12/12	12/13	14/19	14/15	29/31	23/24	15/16	12/13	11/12	11/13	21/23	7/7	8/8	16/18
Ruhr 13	X/Y	10/10	10/13	11/13	11/20	12/14	28/30	17/19	15/16	13/13	10/11	10/11	24/25	6/9	8/12	17/17
Ruhr 18	X/Y	9/10	11/13	9/9	13/17	14/14.2	28/29	17/23	14/17	11/14	8/11	9/14	22/22	9/9.3	8/11	15/15
A1^a	X/Y	11/11	9/12	11/14	13/15	14/16	29/32	19/20	15/16	11/12	10/12	10/10	21/21	9.3/9.3	8/8	14/17
A39	X/X	10/11	11/12	11/12	13/16	15/16	28/31.2	20/25	15/16	12/12	8/12	10/13	22/24	9/9.3	9/11	16/17
BAB 3327^a	X/X	10/11	11/12	9/11	13/18	14/16	30/32	19/19	15/16	11/12	10/12	10/13	20/21	7/9.3	8/9	14/17
A4	X/X	12/12	8/12	11/12	13/16	14/14	30/30.2	20/20	15/17	12/12	10/11	11/13	20/24	6/9	8/9	17/17
A8	X/X	9/11	10/12	10/13	12/12	14/15	27/30	19/25	14/18	12/12	10/13	12/16	21/21	7/9	8/8	17/17
A9	X/X	9/10	9/11	9/11	16/17	14/15.2	28/30	20/26	16/17	11/12	7/9	12/13	22.2/25	6/6	8/11	15/18
SPAST 1	X/X	11/12	8/12	11/13	13/17	13/14	29/31.2	17/23	16/19	10/12	10/11	10/13	19/21	6/8	8/8	14/18

^a STR alleles consistent with a parent-child pair.

STR allele sizes are separated by a “/”. If only a single STR allele was present, it is listed once on either side of the “/”. Raw electrophoretic data available upon request.

Table S3. STR alleles indicate that subjects with identical CNVs are unique individuals.

References

1. Shoukier, M., Neesen, J., Sauter, S.M., Argyriou, L., Doerwald, N., Pantakani, D.V.K., and Mannan, A.U. (2009). Expansion of mutation spectrum, determination of mutation cluster regions and predictive structural classification of *SPAST* mutations in hereditary spastic paraplegia. *Eur J Hum Genet* 17, 187-194.
2. Boone, P.M., Liu, P., Zhang, F., Carvalho, C.M.B., Towne, C.F., Batish, S.D., and Lupski, J.R. (2011). *Alu*-specific microhomology-mediated deletion of the final exon of *SPAST* in three unrelated subjects with hereditary spastic paraplegia. *Genet Med* 13, 582-592.
3. Álvarez, V., Sánchez-Ferrero, E., Beetz, C., Díaz, M., Alonso, B., Corao, A.I., Gámez, J., Esteban, J., Gonzalo, J.F., Pascual-Pascual, S.I., et al. (2010). Mutational spectrum of the *SPG4 (SPAST)* and *SPG3A (ATL1)* genes in Spanish patients with hereditary spastic paraplegia. *BMC Neurol* 10, 89.
4. Miura, S., Shibata, H., Kida, H., Noda, K., Toyama, T., Iwasaki, N., Iwaki, A., Ayabe, M., Aizawa, H., Taniwaki, T., et al. (2011). Partial *SPAST* and *DPY30* deletions in a Japanese spastic paraplegia type 4 family. *Neurogenetics* 12, 25-31.
5. Sulek, A., Elert, E., Rajkiewicz, M., Zdzienicka, E., Stepniak, I., Krysa, W., and Zaremba, J. (2013). Screening for the hereditary spastic paraplaegias *SPG4* and *SPG3A* with the multiplex ligation-dependent probe amplification technique in a large population of affected individuals. *Neurol Sci* 34, 239-242.

6. Loureiro, J.L., Brandão, E., Ruano, L., Brandão, A.F., Lopes, A.M., Thieleke-Matos, C., Miller-Fleming, L., Cruz, V.T., Barbosa, M., Silveira, I., et al. (2013). Autosomal dominant spastic paraplegias: a review of 89 families resulting from a Portuguese survey. *JAMA Neurol* 70, 481-487.